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A Comparative study of Autonomic functions and serum levels of 
Vascular Endothelial Growth Factor in Psoriatic skin and 
Psoriatic arthritis patients
Aim: To access and compare the Autonomic functions (ANS) and serum levels 
Vascular Endothelial Growth Factor (VEGF) in Psoriatic skin (Ps) and Psoriatic 
Arthritis (PsA) patients.
Materials and Methods: The study contains three study groups containing 15 
men and women of age between 20- 40 years with normal resting blood 
pressure. Those with skin lesions and no clinical evidence of arthritis comes 
under Ps group and those having clinical evidence of arthritis with or without 
skin lesions comes under PsA. All the 90 individuals are subjected to 5 minute 
Resting HRV and Orthostatic, Isometric Hand Grip, Cold Pressor, Deep 
breathing and Valsalva tests. Serum was collected and VEGF analysed using 
standard ELISA kit.
Results: The patient groups showed increased LF, LF/ HF ratio, serum VEGF 
and also elevated diastolic blood pressure in isometric hand grip, cold pressor 
test. The HF, 30/15, E/I and Valsalva ratio. Inter comparison between Ps and 
PsA is statistically significant. 
Conclusion: ANS dysfunction is present in both Ps and PsA patients in form of 
sympathetic over activity and parasympathetic withdrawal and elevated serum 
VEGF levels. The ANS dysfunction is more in PsA and no significance of 
serum VEGF values between the groups. VEGF value reflects the disease 
severity.
Key words: ANS functions, Psoriatic skin, psoriatic arthritis, VEGF, Resting 
HRV
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INTRODUCTION 
 
Psoriasis is a chronic systemic immune mediated 
inflammatory disease with a wide spectrum of clinical 
manifestation affecting approximately 2 – 4 percent of 
general population (Menter et al)
1
. Psoriasis is a 
noncontagious primary dermatological disorder affecting 
skin and nails. 
 
The exact cause of the disease is obscure, but 
genetics, immunity, environmental and psychological 
factors plays keen role in development and progression of 
the disease (Visnja et al)
2
. Though the etiology is not 
defined, the disease follows relapsing, exacerbation and 
remitting course.  
 
It can affect any age, from infancy to old age, but the 
usual age of onset is between 25- 30 years. Incidence of 
psoriasis shows no sexual predilection,  but women have 
earlier age of onset
3
. Around30percent of psoriatic patients 
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have a family history of disease, either in first or second 
degree relatives.  
The most common skin manifestations are dry itchy 
erythematous plaques with asymmetrical borders, and 
silvery white scales due to hyper proliferation of skin  
(Steven R et al)
4
. The white scales are accumulation of the 
hyper proliferated skin cells waiting to shed and the 
erythema is due to increased blood supply of the epidermis 
to support hyperproliferation.  These skin lesions are raised 
and causes thickening of skin.  The lesions of skin vary in 
severity from localized lesions to lesions involving entire 
skin. The lesions after healing causes hyperpigmentation 
without scar formation, because the lesions involve only the 
superficial layer of skin.  
 
  Almost 40-50 percent of all psoriasis patients develop 
distinctive nail changes. The appearance and consistency of 
nails are altered. These nail changes are due to 
inflammation of nail matrix or nail bed or involving both. 
The common expression of nail psoriasis is pitting of nails 
and distal onycholysis  (Hermenio)
5
.The other signs are 
yellow discoloration, paronychia, subungal hyperkeratosis, 
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and onychodystrophy. Patients with involvement of nails 
report to have higher prevalence of PsA. Almost 90 percent 
of patients with arthritis have nail involvement.  
 
Psoriasis has a significant systemic involvement 
including joint and soft tissue and mucous membrane 
inflammation, eye, cardiovascular and intestinal 
problems
6 ,7
. Psoriasis has increased prevalence of 
conventional cardiovascular risk factors which not only 
contribute to overt disease but also to subclinical 
manifestations (A M Tobin)
8
. Psoriasis alone is considered 
as a risk factor of developing coronary heart disease and the 
risk increases with severity of the disease. There are variety 
of ocular manifestations including conjunctivitis, dry eye, 
episcleritis, and uveitis. The mucous membrane 
inflammation manifestation as painful mouth ulcers and 
urethritis. 
 
               The other auto immune manifestations are 
inflammatory bowel disease, and multiple sclerosis. Not 
only auto immune diseases, some lymphomas are also 
associated with psoriasis. The lymphomas assoc iated with 
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psoriasis are cutaneous T cell lymphoma, Hodgkin’s 
lymphoma and Non- Hodgkin’s lymphoma.  
 
Psoriatic arthritis (PsA) is a seronegative  chronic 
inflammatory musculoskeletal disease affecting 7 -20 
percent of patient with skin psoriasis. Like skin disease the 
clinical manifestation of arthritis has wide spectrum of 
manifestation like monoarticular, oligoarticular, and 
polyarticular joint involvement.   Any joint can be affected 
by PsA.  
 
Apart from joint manifestation of arthritis , 
inflammation of tendons and ligaments is common in PsA. 
This inflammation is called as enthesitis and it is 
characteristic of PsA.  The cause of PsA is same as th at of 
skin disease but the reason for only some of the skin 
disease patients developing arthritis and other severe 
manifestations is abstruse. It is a long term manifestation 
affecting at any age.  
 
  In about 70 percent of PsA patients, skin 
manifestations develop first, and then musculoskeletal 
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manifestation develops after a variable duration. PsA and 
skin manifestation develop synchronously in 15 percent of 
patients.  In the remaining 15 percent of PsA patients 
musculoskeletal manifestations develop first  and skin 
lesions develop later in their life. The course of the disease, 
its response to treatment, and prognosis is highly variable.  
 
  Clinical manifestation of PsA is joint pain, swelling, 
inflexibility, erythema, reduced agility of involved joints. 
The dispersion of joints involved in PsA is frequently 
asymmetrical, but as the number of joints involved is  
amplified, there is a tendency toward symmetric 
involvement. 
 
  The pathogenesis is same for both the skin and joint 
manifestation. It is a multi -genic autoimmune disease. The 
common manifestation is hyper-proliferation and 
angiogenesis which is formation of new blood vessels from 
pre –existing vessels, that aids proliferation.  Vascular 
Endothelial Growth Factor (VEGF) is a signalling protein 
that is one of the essential component for angiogenesis. 
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VEGF causes proliferation, sprouting, migration of 
endothelial cells (Ferrara et al)
9
. 
 
  VEGF is a potential survival factor for endothelial 
cells in physiological and pathological conditions. VEGF 
has stimulatory effect of recruitment of inflammatory cells. 
In angiogenesis it promotes the expression of protease in 
the pericellular matrix degeneration. It is a permeability 
factor which increases the permeability of endothelial cells. 
It forms vacuoles, fenestrations, intracellular gaps and 
vesico- vascular organelles.  
 
  VEGF is elevated in site of skin lesions as well as in 
the inflammed synovium in psoriasis. The serum level of 
VEGF in serum correlates with the disease severity.  
 
  Psoriasis is a systemic disease and also involves the 
Autonomic Nervous System (ANS). Heart Rate Variability 
measurement is a non –invasive technique that assess the 
ANS functions. It can measure the sympatho –
parasympathetic balance.  The symptoms of impa ired 
sympatho –  parasympathetic balance may not be present or 
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non-specific in psoriasis. By eliciting ANS function tests, 
along with resting HRV, the presence and extent of ANS 
dysfunction can be found in psoriatic skin and psoriatic 
arthritis patients.   
 
  The early development of cardiovascular disease 
is psoriatic patients is well established. The reason is 
multiple risk factors like early atherosclerosis, metabolic 
syndrome, and associated ANS dysfunction. The epidermal 
homeostasis is tightly governed by the sympathetic nerves 
of skin and the sympathetic system checks the rate of 
proliferation and cornification of keratinocytes. In psoriasis 
due to unknown antigen trigger the immune cells are 
activated and continuously produce activated cytokines 
which end in hyperproliferation. The sympathetic system is 
over activated to control the local proliferation. Similarly 
in PsA the inflammation triggers sympathetic nervous 
system and hypothalamo pituitary adrenal axis to secrete 
catecholamines and corticosteroid respectively and end in 
ANS dysfunction. 
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  By conducting ANS study the pathogenesis and 
progression of psoriasis can be understood and aids in 
treatment of the disease. Though psoriasis is a well-known 
old disease the cure for the disease is yet to be found.  
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REVIEW OF LITERATURE 
 
2.1 PSORIASIS HISTORY 
  Since ancient times psoriasis is a well -known 
dermatological disease.  It is mentioned as ‘tzaraat’ in 
Bible’s book of Leviticus, which is believed as psoriasis by 
scholars. It is also mentioned that ‘tzaraat’ was caused by 
sins. Hippocrates 460 – 377 BC, described many skin 
diseases as lepra, leichan, alphos, psora. Psoriasis was not 
exactly described by him, but he included many itching and 
scaling skin disorders under this condition.  
 
                In India Ayurvedic medicine is being practiced 
since antiquity. CharakaSamitha, an ancient Ayurvedic 
scholar, in his book mentioned a disease ‘Khusta’ which is 
believed to be leprosy. The works of PaulRichteret,al
10
.
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suggested that the disease is psoriasis. It was in the fi rst century in 
Roman Empire psoriasis was first described by Cornelius Celsus. 
He described it as scaling lesions of skin also affecting nails. 
Celsus used pitch and sulphur for treating it. He did not use the 
word psora, or psoriasis , Bechet, PE et al (1936)
11
. 
 
               It was Galen who coined the word ‘psora’. He described 
the term for seborrheic dermatitis which has itchy and scaly 
eruptions. Many other persons used the term psora  to describe the 
skin disease similar to psoriasis. In middle age nothing much was 
known about the prevalence and treatment of psoriasis. In the eighth 
century, the Arabian physicians were the first to distinguish 
psoriasis from other scaling skin diseases  and they used a kind of 
psychotherapy in treatment  (Shafii, M.etal.1979)
12
. Psoriasis was 
mentioned as ‘lepragrecorum’ by professor Hieronymus Mercurialis 
in his book of skin diseases in sixteenth century.   
 
 In 1808 psoriasis was first recognized as a separate skin 
disease (WillanR. et al)
13
. Robert Willan (1757 –  1812) described 
some papulosqumous diseases. He differentiated psoriasis and 
leprosy, mentioned as psoraleprosa and lepragrecorum. He also 
noticed psoriasis more common in extensor surfaces, scalp and 
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affects nails. In 1841, Ferdinand Von Hebra an Austrian 
dermatologist, was the first to name the condition as ‘Psoriasis’ 
derived from the Greek word psora, which means itch
14.
 He also 
described psoriasis as a separate skin disease and described its 
various manifestations.  
 
  In the nineteenth century varieties of psoriasis has been 
described, like pustulosa generalisata by Von Zumbush 1910, and 
psoriasis palmo- plantaris by Barber – Konigsbeck. Some of signs 
were also described during this period like Kobner phenomenon in 
1872, by Heinrich Kobner and Heinrich Auspitz described Auspitz 
sign. Auspitz also introduced the pathophysiological terms like 
acanthoma and parakeratosis typical for psoriasis.  
 
 Micro morphology of psoriasis was described by Willam 
Munro, Hebra, and Unna. They described accumulation of 
neutrophils in stratum corneum of skin and used the term ‘micro 
abscesses’.  During early twentieth century Woronoff (1926) 
described Wornoff ring around psoriatic plaques. In 1927 
FranjoKogoj described the spongiform pustule in pustular psoriasis. 
Van Scott, in 1963 demonstrated the hyper proliferation of 
epidermis in psoriatic skin.  
12 
 
2.1.2CLASSIFICATION OF PSORIASIS 
There is no single classification of  psoriasis that satisfies all 
the clinical manifestation of the disease. The criteria used are 
intermixed and the subclasses are non-exclusive. 
According to the spectrum of clinical manifestations the following 
classification is commonly used.  
S. No Classification Salient Clinical features 
1 Psoriasis vulgaris 
Chronic plaque like, 
stationary psoriasis 
2 Guttate psoriasis Small ,drop like spot lesions 
3 Pustular psoriasis 
Pus filled straw colored 
blister lesions 
4 Erythrodermic psoriasis  
Predominant erythema, 
limited scaling 
5 Nail psoriasis Characteristic nail changes 
 
2.1.3 Pathogenesis  
              Skin is the first protective barrier, the largest and complex 
organ of body, containing neural networks, glands, connective 
tissues, blood vessels and immune cells. It also has homeostatic 
functions, modulated by local and systemic factors. E pidermal 
homeostasis is maintenance of its structure and the balance between 
proliferation and cell loss either by desquamation (skin shedding) or 
apoptosis (Stark HJ et al 2006)
15
. 
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The stem cells present in the basal layer of epidermis 
undergoes continuous proliferation and provides new cells for 
renewal of cells lost by routine turn over and also during injury  
(Blanpain, C et al 2009)
16
.The basal cells on proliferation give rise 
to keratinocytes (squamous epithelial cells), the young skin cells, 
which ascend up to superficial layer of skin the stratum corneum 
where they differentiate to corneocyte. Corneocytes are non -living 
epidermal cells which are shed by the process called as 
desquamation or undergo apoptosis.  
 
Cornification is a process whereby living  keratinocytes are 
differentiated into non-living corneocyte.  Normally the 
keratinocytes takes fourteen days to differentiate to corneocyte, 
during which it ascends from the basal layer to the superficial layer 
the stratum corneum.  A Cornified layer is p resent in outermost 
layer of epidermis, which is formed by the lipids (mainly 
ceramides) present in cell membrane and their covalently linked 
structural proteins. 
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Factors affecting epidermal homeostasis are  
1) The  Ceramides:  
The lipids which are synthesized in the keratinocytes are stored 
in lamellar bodies and secreted as intercellular domains of the 
uppermost layer of epidermis. These lipids form a water 
impermeable barrier membrane in the skin. There are several 
lipids present in barrier layer of which ceramides are important 
and found in higher concentrations  (Candi E, et al 2005)
17
.These 
ceramides acts as signalling molecule and regulates the 
proliferation, differentiation and apoptosis of cells  (Hannun, YA 
et al)
18
.  
 
2) The Proteinase: 
Suprabasal keratinocytes express inactive protease  (Brattsand 
M et al 1999)
19
, of which those belong to kallikrein family of 
serine proteases is important. Based on their proteolytic 
domain, these proteases are classified into cysteine, threon ine, 
metalloproteinase, and serine proetinase. These enzymes are 
activated in stratum corneum and appear in the intercellular 
spaces and they play a role in desquamation.  The 
differentiation program of epithelium requires these proteases 
help in detachment of Corneocytes from one another without 
15 
 
disruption of the epithelial barrier. Serine proteases inhibitors 
on tropical application have shown to accelerate the barrier 
recovery after abrogation (Hachem JP et al 2006)
20
. Thus 
serine proteases cause the lysis of corneodesmosomes 
(Kanitakis J et al 2006)
21
 and proved to play a role in 
epithelial barrier function.  
3) Epidermal junctions and the adherent junction proteins:  
Epidermal junction is the basement membrane synthesized by 
the dermal fibroblasts and the basal keratinocytes. It acts as a 
mechanical support and helps in adhesion of epidermis and 
dermis. It plays an important role in the regulation of 
exchange of metabolic products between dermis and 
epidermis. The keratinocytes in basal layer are adherent to one 
another and also to the basement membrane through gap 
junctions, adherent junctions out of which desmosomes is 
most characteristic in this layer. Maintenance of  desmosomes 
in the basal layer is important in epidermal homeostasis.   
4) Intracellular and extra cellular Calcium:  
In the basal layer formation of new adherens junction and 
desmosomes requires efficient concentration of extracellular 
calcium (Hennings H et al)
22
. In cell culture medium of 
keratinocytes, raising the calcium concentration from 0.05 
16 
 
mM to 1.2 Mm stimulates the cells to form strong cell to cell 
adhesions. Also proper calcium concentrations, both 
intracellular and extracellular are essential for proper 
proliferation and cell differentiation of keratinocytes.  
5) Secretory function of keratinocytes:  
Keratinocytes produce Catecholamines locally  (Christian E et 
al)
23
and also wide varieties of cytokines like tumor necrosis 
factor and IL 1α, IL 1β and IL -6 in addition to keratin protein. 
Any interruption in epidermal barrier causes increased 
secretion and expression of these cytokines. These cytokines 
stimulate synthesis of lipids; regulate their metabolism helps 
in maintaining the barrier homeostasis function of epidermis.  
6) Sympathetic receptors:  
Skin is another important peripheral endocrine organ that is 
regulated by central regulatory mechanisms. Keratinocytes 
express beta 2 adrenergic receptors  (Tseraidis GS et al)
24
. 
These receptors on activation control the proliferation of 
keratinocytes by protein - kinase dependent pathway(Puller et 
al)
25
. This receptor also controls the rate of migration of 
keratinocytes by cAMP independent pathway.  Catecholamines 
increase the calcium entry and aids proliferation, migration 
and differentiation of keratinocytes. The expression of these 
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receptors is more in basal layers of epidermis than in stratum 
corneum. They also play important role in re -epithelialization, 
and wound healing.  
There exist two hypotheses for the pa thology of psoriasis. The 
first hypothesis states that psoriasis as a purely skin disease 
involving the skin only. The disease is due to faulty 
hyperproliferation of epidermal cells the keratinocytes, with their 
incomplete differentiation. These keratinocy tes also show reduced 
apoptosis. The support to this hypothesis is that in some patients the 
disease involves only the skin and do not show any systemic 
manifestations. This hypothesis is not accepted since it is well 
accepted that psoriasis is a systemic disease and patients who show 
initial skin manifestation later develop systemic manifestations.  
 
The second hypothesis states psoriasis is an immune mediated 
disorder (Wu,JJ. et al2012)
26
.The hyperproliferation is secondary to 
inappropriate activation of cell mediated immune system. Skin has 
effective immunological surveillance system. It has antigen 
presenting cells, T cells, tissue macrophages, granulocytes, 
fibroblasts, capillary endothelial cells of dermis, mast cells, 
cytokines synthesized locally. All the above mentioned cells 
together with draining nodes constitute skin a primary lymph organ. 
18 
 
These cells interact by cytokines in response to antigens which are 
presented by the antigen presenting cells.  
 
The antigen may arise from any stimulus like infection, 
chemicals, irritating substances, ultraviolet rays, drugs or even 
stress. Normally there is controlled response, but in psoriasis the 
response is prolonged, uncontrolled and there is imbalanced 
secretion of cytokines (Krueger JG.et al)
27
. 
 
In psoriasis due to some unidentified antigen stimulation the 
epidermal dendritic cells the Langerhans  cells, which recognizes 
and captures the antigen. These cells migrate to local lymph nodes 
and present them to the T- helper cells.  In psoriasis there is 
immune deregulation and the functions of T cells are not regulated. 
Any stimulation of T cells causes a cascade of inflammatory 
responses in psoriasis.  
 
The activation of T lymphocytes releases pro inflammatory 
cytokine Tumor Necrosis Factor- α and interleukin -2. The activated 
Langerhans cells release IL12. These cytokines ultimately regulate 
the genes that code the transcription of other cytokines like, 
interferon gamma, Tumor Necrosis Factor etc, which helps in 
19 
 
proliferation, differentiation and maturation of T cells into memory 
effector T cells (memory T cells to that particular antigen). These T 
cells migrate to the skin from the lymph node; accumulate around 
the dermal blood vessels. These events are a normal response of 
epidermis to any antigen, but in psoriasis that will be initial step in 
series of immunologic changes resulting in a psoriatic plaque.  
 
 The production of several cytokines around dermis and in 
epidermis creates a pro- inflammatory environment, where the 
endothelial cells of dermal vessels initiate to express adhesion 
molecules like Intra Cellular Adhesion Molecule –  1(CD54 or 
ICAM-1 ), E-selectin(CD62E), Vascular Cell Adhesion Molecule -
1(VACAM-1 or CD 106). The molecular alterations in the skin 
cause neutrophils and lymphocytes to migrate to dermis. Among the 
pro- inflammatory chemokines, IL 8 is related to Margination of 
neutrophils plaque psoriasis. These leucocytes are attracted by the 
inflammatory chemokines released by the keratinocytes  (Salgado A 
et al)
28
. 
 
 The Dendritic cells in skin which is CD+11c positive, 
produces TNFα, IL-12, IL23 and IL20.These cytokines ultimately 
regulate the genes that code the transcription of other cytokines 
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like, interferon gamma, Tumor Necrosis Factor etc, which helps in 
proliferation, differentiation and maturation of T cells into memory 
effector T cells (memory T cells to that particular antigen). These T 
cells migrate to the skin from the lymph node; accumulate around 
the dermal blood vessels.  
 
After the T cell migration there is subsequent increase in 
migration of other leukocytes especially neutrophils and 
lymphocytes into the dermis and there is increased proliferation of 
keratinocytes. The hyper proliferative response of keratinocytes 
decreases the time of transit from base of epidermis to the 
superficial corneal layer. There are three phases in cytokine 
pathway (Kunz M et al)
29
.  
 
Phase I:  
Production of Interferon Gamma by CD3 + Th 1 cells, inn response 
to IL12 is phase I of cytokine pathway.  
Phase II: 
Continuous activation of keratinocytes and formation of TGFβ in 
the inflammatory field is the initial step. IL12, TGF β, IL  23, 
induces the production of IL17, from the T cells.  
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Phase III: 
IL 17 acts with IL 20, IL 22 and IL24 produced by activated 
macrophages ultimately results in enchased keratinocyte  activation, 
proliferation which belongs to phase III of cytokine pathway. The 
transit time reduces from the normal 28 days  to 2-4 days in 
psoriasis.             
 
 2.1.4 Diagnosis:  
The lesions in skin in due course of disease in the same patient 
differ over time. There is no specific diagnostic test to predict the 
future psoriasis and so patients presenting first time with psoriatic 
lesions are diagnosed as ‘latent psoriasis’ 30. Patients showing 
subjective variation are diagnosed as ‘minimal psoriasis’ due to 
lack of validated criteria. The signs of psoriasis are called as 
‘stigmata of psoriasis’ . 
 
Signs 
1. Hyperkeratotic plaques on the skin surface with or without 
scaling. 
2. In palms and soles keratolysis like lesions.  
3. Severe dandruff like lesions well beyond the hair line. 
4. Nail pitting 
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5. Multiple sterile paronychia.  
6. Subungal hyperkeratosis  
7. Onycholysis in the absence of fungal infection.  
8. Sharply marginated penile erythema without fungal infection.  
9. Well defined erythematous plaques which may be 
symmetrical or not in distribution. 
10.  Healed lesions shows hyperpigmentation and shows no 
scarring, since psoriasis involves only epidermis.  
11.  Scaling of lesions is characterized to psoriasis, but it may be 
absent in severe form and in acute lesions. The scales are 
silvery white, and vary in thickness.  
12. Auspitz sign: removal of scale from lesions shows tiny 
bleeding points due to hyperproliferation of dermal blood 
vessels. 
13. Koebner phenomenon:  development of new lesions at site of 
traumatized skin (Griffiths, C et al)
31
.      
                                                                                                                         
   In most patients diagnosis is established by the clinical 
presentation, family history, and by showing the presence of 
Auspitz sign and by the history of Koebner phenomenon. Very 
rarely to diagnose, biopsy of skin is essential in case of psoriasis. 
The predominant characteristic microscopic features of psoriasis are  
23 
 
 Epidermal hyperplasia 
 Inflammatory infiltrate 
 Vascular changes 
The epidermal changes are keratinocyte hyperplasia, 
attenuated or absent granular cell layer with poor keratinocyte 
maturation, differentiation (McGrath JA et al)
32
 along with 
epidermal thickening. The epidermal projections are clubbed and 
interdigitate with dermis. The cells in stratum corneum also show 
poorly differentiated, immature cells with nucleus  (Haftek M et 
al)
33
. Normally the corneocytes lack nucleus on maturity.  All these 
changes in epidermis cause thick plaques with scales.  
The dermis shows inflammatory infiltrate initially, and these 
infiltrates evade the epidermis by exocytosis. The infiltrates are 
mainly composed of T helper cells, cytotoxic CD8+ cells and also 
neutrophils. The neutrophils in the infiltrates form the spongiform 
pustule of Kogoj, and Munro microabscess, which is characteristic 
microscopic finding of psoriasis  (Kaneko F et al)
34
. 
The vascular changes include increase in the number and 
density of the superficial vascular plexus  (Shilpa Gupta et al)
35
. The 
tortuosity of vessels is increased and venulization of capillary 
network appears (Rubin's Pathology)
36
. The capillary at the site of 
24 
 
lesions appears like vein and the capillary network is called as High 
Endothelial Venules (Hani A. et al)
37
. 
 
 2.1.5.  Grading the severity of psoriasis:  
The severity of psoriasis cannot be graded like other chronic 
diseases by natural history. Psoriasis is  graded by measuring the 
clinical remission, number of hospital admissions, consultations, 
number of flare ups, assessing the skin area involvement at the 
present time. This grading usually will not give information about 
social or psychological consequences. Clinically Psoriasis Area and 
Severity Index (PASI) is widely used and accepted. PASI grading  is 
based on the severity of lesions, along with the specific site and 
area of involvement. The score ranges from 0-72, where ‘0’ score 
indicate no disease and ‘72’ score indicates maximal disease  
(Langley RG et al)
38
. 
 
Calculations of PASI score:  
Whole body is divided into four sections 
 Head (H) - constitutes 10% of person’s skin.  
 Upper Limb or Arms (A) – constitutes 20% of person’s skin.  
 Trunk (T) –  constitutes 30% of skin. 
 Lower Limb or Legs (L) –  constitutes 40% 0f skin.  
25 
 
The percentage of skin involved in each section is estimated 
separately, then it is graded according to the following grade.  
 Grade 0 - 0% or no skin is involved. 
 Grade1 - 10% of skin is involved. 
 Grade 2 - 10 –  20% of skin is involved. 
 Grade 3 - 30 –  49% of skin is involved. 
 Grade 4 - 50 –  69 % of skin is involved. 
 Grade 5 - 70 –  89% of skin is involved. 
 Grade 6 - 90 –  100% off skin is involved. 
Again in each section the severity is calculated by the three 
important clinical signs 
1. Erythema or redness  
2. Induration or thickness 
3. Desquamation or scaling 
Again the severity parameters are measured on a scale from 0 -4. 
Scale 0 means none and scale 4 means the maximum.  
For each section of skin, all the severity parameters are calculated 
summed up and multiplied by the area score and by the weight of 
respective section (Dennis Thompson  etal)
39
. 
 
SECTION WEIGHT 
Head 0.1 
Upper Limb 0.2 
Trunk 0.3 
Lower Limb 0.4 
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The disadvantage in PASI scoring was the score is non - 
reproducible. Many modifications of PASI scoring have been 
developed recently. The adapted PASI scoring is an important 
modification in which the psoriatic lesion area section is not 
converted into area grade, but it is calculated in form of continuous 
variable. This modification improved the power of clinical trial.  
 
The modification commonly used in PASI scoring is Computer 
aided psoriasis continuous area and the severity score mentioned as 
cPcASI (Louden BAet al)
 40
. In this cPcASI system patient’s 
affected area was photographed and the area is automatically 
assessed by the computer instead of manual measurement by the 
physician. Increased scoring in the PASI indicates severe form of 
disease and the clinical severity is difficult to  say by any specific 
PASI score. To overcome this problem psoriasis severity evaluation 
system includes Lattice- system physician’s Global Assessment 
(LS- PGA), and the Psoriasis Global Assessment (PGA) system ) 
Robinson A et al
41
. 
 
2.1.6 Other manifestations:  
Psoriatic skin disease is most commonly associated with nail 
changes. Finger nails are most  commonly involved than the toes.  
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Psoriatic arthritis is the second common clinical manifestation of 
psoriasis. Apart from psoriatic arthritis , it is associated with a 
number of co- morbidities like cardio vascular disease, 
Inflammatory bowel Disease (IBD), obesity, metabolic syndrome,  
sleep apnoea syndrome, psychiatric disorders like depression, solid 
tumor of specific sites like  lung, kidney, colon, certain lymphomas.  
 
Nail manifestation: 
The most common characteristic manifestation of psoriatic nail 
changes is described below;  
 Pitting of nail  
 Onycholysis  
 Oil spots  
 Sub ungula hyperkeratosis  
Mild nail manifestation in form of pitting is most commonly seen 
in psoriatic patients. Severe form of nail changes is usually 
associated with psoriatic arthritis and psoriatic scalp invol vement. 
 
Geographic tongue:  
 It is otherwise called as benign migratory glossitis. It a local 
disorder of tongue due to inflammatory of mucous membrane and 
loss of filliform papillae. It appears as red patches with serpiginous 
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borders similar to a map. The lesions are asymptomatic and 
migratory in nature. It is considered as an oral variant of psoriasis 
since the histological features like acanthosis, clubbing of rete 
ridges, neutrophil infiltrates and focal parakeratosis are similar to 
psoriasis (Robyn S Fallen et al)
 42
.  
 
Obesity and metabolic syndrome: 
The important source of IL 6 is adipose tissues. Inflammation 
in any site of body is associated by certain cytokines derived from 
adipose tissue and liver and the cytokines are IL - 1, IL – 6, TNF – 
α43. Certain cytokines are common in the pathology of psoriasis and 
obesity, metabolic syndrome. Psoriasis is associated with these 
disorders, but it is not revealed which comes first. It is suggested 
that both these disease has a common genetic background  (Sterry 
Wet al)
44
 and also obese psoriatic patient  show severe form of 
disease. 
 
Cardio vascular disease: 
The process of atherosclerosis involves inflammation and in 
psoriasis there is immune mediated systemic inflammation  (Kremers 
HM et al)
45
.  Several studies have proved psoriatic patients have 
increased risk of arterial and venous vascular disease and 
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myocardial infraction. Metabolic syndrome, common is psoriasis is 
associated with hypertension, obesity, dyslipidemia, insulin 
resistance, and patients with psoriasis also have elevated C- 
Reactive Peptide (CRP), homocysteine, prothrombotic state like 
high fibrinogen, TNF α, and other cytokines which are all proved 
risk factor for cardiovascular disease. Local and systemic 
inflammation results in the pathogenesis of coronary heart disease.  
The activated helper T cells release many pro inflammatory 
cytokines which causes the increased epidermal turn over, can also 
aids in initiation and progression of atherosclerotic plaques 
formation (Oliver et al)
46
. The role of cytokines in atherosclerosis is 
well established. 
 TNF –α and IL- 1 causes transient reversible endothelial 
dysfunction initially. On prolong stimulation it causes 
permanent irreversible endothelial dysfunction.  
 IL- 6 and soluble IL- 2 causes impaired microvascular 
dysfunction. 
  Impaired  TNF –α raises the adhesion molecule expression in 
endothelium, aids in attraction and adhesion of leucocytes. It 
also stimulates Nitric Oxide Synthase (NOS), and increases 
the levels of Nitric Oxide (Trac YZhu et al)
47
. 
 Nitric Oxide increases the oxidative stress in the endothelial 
cells. 
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Thus these cytokines causes oxidative stress and inflammation 
which results in increased apoptosis, formation of atherosclerotic 
plaque and thrombus formation ultimately resulting in coronary 
heart disease and stroke. There are several evidence that the 
pathogenesis of psoriasis and atherosclerosis have a pivotal link.  
 Both the disease share some common pathologic features. The 
immunological activities and pro inflammatory cytokines from 
activated cells  play important role in both the disease. Both disease 
share T helper cell mediated immune compromise and same pattern 
of T cell activation and expression. 
 
Figure 2.1 Common pathogenesis of psoriasis and atherosclerosis  
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2.2 Psoriatic Arthritis (PsA):  
Psoriatic arthritis is an immune mediated inflammatory 
musculo skeletal disease showing negative rheumatoid factor in 
serum. PsA involves the musculoskeletal structures of peripheral 
and axial joints and also involves entheses, tendon sheaths.  The 
exact proportion of psoriatic skin patients developing arthritis 
cannot be predicted. On an average the proportion of psoriatic skin 
patients developing arthritis ranges from 6% to 42% worldwide. In 
India the proportion of arthritis developed in skin patients ranges 
from 7-20 percent. 
 PsA develops in patients with severe skin disease usually, but 
in some 12- 15% of patients arthritis appears first then in due 
course of time they develop skin manifestation.70-82% of PsA 
patients have an average duration of 12 years of skin 
manifestations,  later they develop arthritis. In the remaining of 
patients both the skin lesions and the arthritis occurs concurrently 
at the first presentation.  
  PsA also has no sexual predilection like RA where women are 
more predilected. It occurs equally in both men and women in the 
ratio of 1:1. PsA can occur at any age, even children show PsA 
manifestations but it usually occurs in middle age. Children with 
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PsA shows increase incidence of developing uveitis and chance of 
progressing to severe and disabling form of the disease.  
 
2.2.1Clinical presentation: 
  The involved joints show pain or tenderness, swelling, 
stiffness and also tenderness around the joints involving the 
ligaments and tendons. These are the common symptoms and can 
vary from mild to severe forms. The characteristic of psoriatic 
arthritis is it tends to follow a relapsing and remitting course  (Shah 
NM et al)
48
. The clinical presentation is usually preceded by skin 
lesions but in some patients the skin lesions may be occult or left 
un-noticed by the patient.   
   Occult lesions should be searched in extensor surfaces, 
umbilicus, scalp, body folds and nail changes. Enthesitis of Achilles 
tendon and plantar fascia is also common clinical presentation. 
Tenosynovitis of PsA usually affects the flexor tendons rather than 
the extensors tendons. Sacroilitis and conjunctivitis or uveitis is 
common in HLA- B27 (Duarrani et al)
 49
.   
 
2.2.2 Classification:  
In 1973 Moll and Wright was the first to describe the psoriatic 
arthritis and classified psoriasis into five subtypes. There is high 
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degree of overlap between categories within these subtypes and 
hence show limitation in clinical practice.  
1. Distal interphalangeal arthritis (DIP)  
2. Symmetric polyarthritis  
3. Asymmetric oligoarthritis  
4. Spondylo arthropathy  
5. Arthritis mutilans  
 
The pattern of arthritis may change from one form to other in due 
course of time. Patients initially present as asymmetric 
oligoarthritis initially, the as more joints are involved in due course 
of time, and they show symmetrical involvement and the pattern 
changes to symmetric polyarthritis. Similarly the disease initially 
shows more peripheral joint involvement and later progress to 
involve the axial skeleton.  
 
  In 1994 Veale et al
50
 included SAPHO syndrome as a distinct 
subgroup. SAPHO syndrome is a variety of inflammatory disorder 
of bone associated with skin lesions. It includes synovitis, acne 
involving face and trunk, pustulosis involving the palms and soles, 
hyperostosis and chronic recurrent osteomyelitis
51
. 
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CASPAR (ClASsification criteria for Psoriatic ARthritis): 
S. No Diagnostic point Score 
1 Presence of well-established psoriatic lesions  2 
2  A past History of psoriasis, but at present 
there is no lesions 
1 
3  A family history of psoriasis, but no present  
or past psoriatic lesions 
1 
4 Presence of dactylitis or previous history of 
dactylitis recorded by a rheumatologist  
1 
5 Juxtra articular formation of new bone 1 
6 Serum rheumatoid factor negativity  1 
7 Typical psoriatic nail dystrophy like 
onycholysis, pitting, hyperkeratosis.  
1 
 
  It is used in recognized inflammatory joint and articular 
disease. Inflammatory joint disease is diagnosed with the history of 
prolonged morning stiffness or stiffness following prolonged 
immobility, with or without radiological evidence. At least three 
points from the following defined features establish the diagnosis of 
psoriasis. 
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2.2.3. Genetics of psoriatic arthritis:  
Family study among the PsA patients suggested that their first 
degree relatives are in greater risk of developing the disease.  Moll 
and Wright’s family studies indicate the recurrence risk is higher 
among PsA patient’s family. There is a strong genetic association 
for PsA. PsA involves multiple genes and genetic polymorphisms 
also influence it. Some genes with regard to PsA has been iden tified 
and they belong to HLA alleles, MHC class I, Killer Cell 
Immunoglobulin Like Receptor (KIR)genes, TNFα, IL 1, 
IL23Receptor genes. 
 HLA B13, HLA B16 and its splits HLA B38and 39 are 
associated with PsA. 
 -Cw6 is associated with psoriatic skin disease not with PsA. 
The association has distinguished a 100 kb telemetric region 
on a HLA C locus. The true locus is exactly not in HLA C, 
also involves another gene in linkage disequilibrium (Nair RP 
etal)
52
. 
 HLA B 27 and HLA 7 are associated with PsA specifical ly. 
 HLA-C, IL 12 and IL23 R have strong association with PsA.  
 Novel PsA a locus has been identified on locus chromosome 
4q 27 which anchors IL 2 and IL 21genes.   
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 HLA B39, HLA B27 in the presence of HLA DR7 and in the 
absence of HLA DQ 3confers increased r isk of disease 
progression. 
 TNF polymorphisms are associated with erosive arthritis and 
the joint damage progress quickly. It is commonly seen in 
early onset PsA. 
 IL 4 receptor gene is also associated with erosive PsA.  
 
2.2.5 Pathogenesis : 
It is an autoimmune disease directed the joints, tendons and 
ligaments. Chronic auto reactive T cell driven inflammation is the 
main pathogenesis of PsA.  The pathogens encodes the exogenous 
ligands and these ligands activate the T cell in previous 
inflammation. This response in the prior episodes of inflammation 
results in expansion of memory effector T cells. This memory 
effector T cells recognize stress related self –  antigens and initiates 
and maintains the pathways of inflammation mediated by 
transcripition factors, activator proteins, production of cytokines 
and inflammation directed against skin, joints, and musculoskeletal 
structures. 
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2.2.5 Link between skin and musculoskeletal inflammation:    
 Only 13 –  20% of psoriatic skin patients get arthritis and the 
rest do not develop it. Offidani et al
53
 study has proved by MRI and 
X ray finding has proved that there is a subclinical joint 
inflammation in many psoriatic skin diseases that may show 
musculoskeletal syndrome in due course of disease. The activated 
lesions in the skin enters the sub synovial vessels in the joints 
promotes inflammation. Some local factors like trauma, stress, 
infection could promote and initiate innate immunity response that 
rapidly progress to acquired immunity in setting a T cell expansion 
in skin, lymph nodes, soft tissues, joints, tendons.  
 
Skin and joint contain common micro anatomic features like 
differential degree of mechanical stressing, vascular as well as non 
–  vascular tissues and share same antigens. It is very hard to detect 
the specific genes for skin and joint manifestations because patients 
with skin disease may or may not develop joint manifestations. 
Likewise most of PsA patients have cutaneous manifestations. The 
musculoskeletal and skin is not linked by circulating cells, but by 
an abberent response to injury in skin and the joint.  
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2.27. Predictions of worse prognosis:  
The course, the severity and response to treatment in PsA is 
unpredictable. It varies among person to person and even in the 
same person the sub types vary during the course of disease.  
Some of the symptoms and presentation may predict the outcome of 
the disease
54
 and they are 
1. Polyarticular involvement 
2. Erosive arthritis at presentation 
3. Extensive skin lesions 
4. A strong positive family history 
5. Younger age of onset 
 
2.2.8 Other musculoskeletal features:  
 Enthesitis  –  Inflammatory lesions at the site of insertion of 
tendon into the bone. It is seen in 20- 40% of PsA patients. It 
is the first sign of clinical presentation of PsA in 4% of 
patients. Common sites of enthesitis are Achilles tendon, 
insertion site of plantar fascia at the calcaneous bone, 
ligament insertion sites in pelvic bones.  
 Dactylitis –  30-40% 0F PsA patients in due course of time 
develop dactylitis. Dactylitis is complete swelling of the 
finger. One or two fingers are involved at a time and it 
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involves the toes rather than the fingers. Radiographic 
evidence shows erosive arthritis of the involved finger. The 
patients later develop flexor tenosynovitis, soft tissue edema, 
bone edema and also synovitis.  
 Peripheral edema- Distal extremities one or more show 
peripheral edema. I t usually occurs in asymmetric arthritis 
prefentially involving lower limbs.I t can occur at any time and 
is due to extensor tenosynovitis and this local enthesitis. 
There is edema along the whole course of involved tendon. 
This condition is pain less, but the arthritis is painful and 
commonly associated with erosive arthritis  (C. Palazzi et al) 
54
. This condition responds well to oral corticosteroids.  
 Psoriatic onychopachydermaperiositis – This condition is 
seen in severe PsA. It involves one or more distal phalanx 
both in upper limb and lower limb. The involvement of DIP is 
variable and hard to detect due inflammation and edema of 
distal phalanx. Common site of this condition is great toe and 
radiological images of great toe in this condition is called as 
‘Ivory phalanx’  
2.2.9. Pathologic cartilage resorption 
Loss of cartilage is common in PsA and its radiological 
evidence is narrowing of joint space.  Levels of Matrix Metalo 
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Proteinases (MMPs) and their tissue inhibitors Tissue Inhibitor 
Metalo Proteinases (TIMPs) are elevated in the synovial lining 
cells and the subsynovial cells in  affected joints of PsA patients  
(C Ribbens et al) 
55
. 
Immune histochemical studies reveals that MMP –  9 in 
vasculature and MMP – 1, MMP 2 and MMP 3 (Senger DR et al)  
56
, TIMP 1, TIMP2, m RNA were elevated similar to that of 
Rheumatoid arthritis. These immuno pathogenic mechanisms that 
dictate cartilage destruction in PsA are also shared with other 
Spondyloarthropathies.  
 
Altered bone remodelling: 
Bone involvement in PsA is intriguing and has confounded 
attempts to explain it because it is so heterogeneous event in PsA 
patients. Altered bone remodelling (Gospodarowicz D et al)
 57
 and 
new bone formation includes joint ankylosis,  syndesmophyte 
formation at the sites of soft tissue including the enthesis is 
common in PsA. 
PsA involved sites of bone show diffuse bone marrow edema 
and histologically evident as osteitis. The diffuse bone edema at the 
tendon insertion sites is less in comparison to other 
Spondyloarthropathy. 
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In DIP bone edema is common and prominent, and in 
metacarpo phalangeal joints less number is involved and also it is 
less prominent. In knee diffuse osteolytis occurs typically adjacent 
to insertion of tendons and it is seen in one third of PsA patient. 
The osteitis progress to joint destruction.  Osteitis related to several 
TNF transgenic models are conducted. In TNF transgenic mode ls 
the earliest lesion is seen in stromal compartment of enthesis.  
  Radiological evidence of affected bone shows large eccentric 
bone erosions, pencil cup deformities, bone resorption, new bone 
formation, perostiits, ankylosis peripheral joints. Axial joi nt shows 
ankylosis in the peripheral joints and enthesophytes in spine.  
 
4.1. Autonomic Nervous System (ANS): 
   Autonomic Nervous system is a division of Central Nervous 
System (CNS) which controls the visceral motor control and 
ultimately the visceral homeostasis. Apart from skeletal muscle all 
other organs are innervated by ANS. Survival of an individual is 
even possible with the absence of ANS regulation but the body’s 
internal homeostasis is severely compromised. Visceral homeostasis 
is essential for maintaining a dynamic internal environment. 
Dynamic internal environment is essential for proper functioning of  
all cells, tissues, and organ systems.  
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ANS is classically divided into two main divisions  
i. The  sympathetic nervous system- Thoracolumbar division 
ii. The parasympathetic nervous system- Cranioscaral division 
Some considers the enteric nervous of Gastro Intest inal Tract (GIT) 
as a part of ANS, but it is now commonly accepted as a separate 
entity. ANS basically consists of two sets of neurons. They are  
i. The pre- ganglionic neurons also called as connector  
ii. The post ganglionic neurons also called as effector  
iii. The peripheral ganglion 
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Figure 2.2 Autonomic Nervous System 
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Autonomic out flow pattern: 
The pre- ganglionic neurons are present in brain stem and in 
the intermediolateral gray horns of thoracic and lumbar segments of 
spinal cord. The post ganglionic fibers  are present in pre and 
paravertebral chains. The peripheral ganglion is present in the 
peripheral organs which is characteristic of ANS and these ganglion 
acts as relay stations. It provides control loops close to the visceral 
organs innervated by the ANS.  
The ANS innervation is different from somatic innervation, 
ANS involves both the neurons pre – ganglionic and post- 
ganglionic nerve fibres and they link the central portion and the 
visceral structure. ANS is noted for the relay that it makes between 
the CNS and the visceral organ they serve.  
 
Functional and pharmacological features of ANS:  
   Parasympathetic and sympathetic divisions of ANS differ 
anatomically, morphologically, physiologically and 
pharmacologically. Though they operate reciprocally and 
antagonistically their actions are highly controlled and integrated 
thoroughly.  
 Sympathetic activation causes the individuals to mobilize the  
individual and spend the energy and associated with ‘ergo tropic ’ 
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(ergo means energy and tropic means releasing) . In contrast 
parasympathetic activation causes conservation of energy and the 
operation of vegetative functions to conserve energy. Thus fun ction 
provided by parasympathetic system activation is concerned with 
day to day vegetative actions and hence parasympathetic activation 
is called ‘tropotropic (trophos means nourishment).  
 The main neurotransmitters released from ANS nerve fibers 
are Acetylcholine and Nor-Adrenaline. All the preganglionic fibers 
both sympathetic and parasympathetic releases Acetylcholine. All 
post ganglionic parasympathetic nerve fibers and cholinergic 
postganglionic nerve fibers secrete Acetylcholine. Adrenergic post 
ganglionic fibers secrete Nor-Adrenaline.  
Autonomic control of Heart:  
Heart is innervated by both sympathetic and parasympathetic 
nerves. The sympathetic preganglionic fibers originate in the 
intermediate horns of upper 4 or 5 thoracic spinal segments, relay in 
stellate ganglion, reach heart and innervate pacemaker, conduction 
system and also atrial and ventricular muscles. The vagus  
(parasympathetic) nerve originates in the dorsal nucleus of vagus in 
medulla, ends in ganglia close to SA and AV node and the s hort 
post ganglionic nerves supply the pace maker, the conduction 
fibers, and also innervates the muscle fibers but sparsely.  
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Figure 2.3 ANS innervation of heart  
 
The vagus is cardioinhibitory and on stimulation releases 
Acetyl choline from the post ganglionic nerves which makes the 
cardiac fibers less excitable. The acetylcholine increases the 
potassium permeability and cause increased potassium efflux 
resulting in hyperpolarization of membrane. The end result is the 
tissue becomes less excitable. On vagal stimulation the rate of 
pacemaker impulses are reduced, conduction in the conduction 
tissue is slowed, the force of contraction of atrial muscles is 
reduced and the ventricle muscle is least affected.  
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                                Effect of Vagal stimulation on heart  
 
Figure 2.4.        N- Normal heart beats, S- Stimulation, I- 
Inhibition, VE- Vagal escape, SW stimulation to Withdrawal.  
 The impulses from cardio respiratory region of medulla passes 
continually to the heart via the vagus and keeps  a check of heart 
rate and that is called as vagal tone. The vagal tone originates from 
sinoaortic baroreceptors, and the impulses reach medullary cardio 
inhibitory center and send impulses to heart via vagus. Sino aortic 
denervation causes abolition of vagal tone. 
 The sympathetic stimulation causes increase in heart rate 
(chronotrophic), increase in force of contraction (inotropic) and 
also increase in conduction velocity (dromotropic). It also increases 
the excitability (bathmotrophic) and reduces the re laxation of 
cardiac muscle (lusiotrophic).It releases nor adrenaline from the 
post ganglionic nerve terminals. It reduces the potassium efflux and 
causes the opening of transient calcium channels in SA node. The 
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opening of L channels in the cardiac muscles  increase the force of 
contraction. These actions are brought by β 1 receptors  (Frielle T et 
al)
 58
 in the cardiac tissue.  
 There is some degree of sympathetic tone along with vagal 
tone and sympathetic denervation  reduces the heart rate 
considerably. These impulses originate from the medulla and from 
the hypothalamus also. This tone also keep the vessels in partially 
constricted state and plays role in maintaining the vascular 
resistance and in maintaining the blood pressure. 
Normally there exists a balance between sympathetic and 
parasympathetic tone and called as sympathovagal balance. Intrinsic 
heart rate is said to be heart rate of a denerved heart and it is 100 - 
110 beats/ minute. The normal adult resting heart  rate is around 72 
beats / minute and it is said that under resting conditions the 
parasympathetic tone predominates.  
   
                           
Figure 2.5 
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Reflex control of heart rate:  
1) Sinoaortic baroreceptor reflex 
Baroreceptors are mechanoreceptors which are situated in the 
tunica adventia of carotid sinus and transverse arch of aorta, 
supplied by coiled myelinated pressure sensing nerve endings of 
glossopharyngeal and vagus nerve respectively. The afferents reach 
the Tractus solitaries of medullary cardiovascular center.  
 At normal blood pressure there is a low frequency of impulse 
discharge in these nerves and it is responsible for the vagal tone. 
Any increase in blood pressure (upto 180 mmHg) increases the 
discharges from the baroreceptors which reduce the heart rate and 
vice versa occurs in decrease in blood pressure ( upto 60 mmHg).  
Bilateral sinoaortic denervation increases the heart rate and 
similarly bilateral clamping of carotids below the carotid body 
increases the heart rate. 
                  
Figure 2.6: Functioning of baroreceptors  
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2) Reflexes from peripheral chemoreceptors:  
Chemoreceptors is stimulated by hypoxia, hypercapnia , and 
hydrogen ions. On stimulation per se it causes decreased heart rate, 
but indirectly the stimulants of chemoreceptors increases the heart 
rate. 
3) Bainbridge reflex:  
 Venous engorgement of the right side heart causes increase in 
heart rate and brought by stretch receptors and the effect is 
abolished by bilateral vagotomy. The afferent is vagus and the 
efferent is both sympathetic and vagal nerves.  
4) Sinus Arrhythmia:  
Variations of heart rate occurs during the phases of 
respiration. The heart rate is increased during inspiration and 
reduced during expiration. It is well appreciated in children and 
young adults and diminishes with age. The reason of increased heart 
rate during inspiration is  
 Alteration in venous return and blood pressure during 
various phases of respiration. 
 Irradiation of impulses from respiratory to cardio 
inhibitory centers.  
 Reflexes from stretch receptors in lungs which is 
changed during the phases of respiration.  
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5) Peripheral receptor stimulation:  
A strong somatic receptor stimulat ion may alter the heart 
rate. A painful stimuli or a strong thermal stimulation 
increases the heart rate.  
Figure 
 
Figure 5.7 sinus arrhythmia  
5) Bezold –Jarish reflex- marked stretching of left ventricle causes 
reduction of heart rate.  
6) Oculocardio reflex: pressure in eyes increases the vagal tone and 
reduces the heart rate.  
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The other factors regulating the heart rate is hormones 
(catecholamines, thyroxine, vasopressin), temperature, levels of 
oxygen, carbondioxide, hydrogen ions.  
 
Heart Rate Variability: 
 The variation of heart rate interval between two beats and 
between the instantaneous heart rate is known as ‘Heart Rate 
Variability’ (HRV). The reason for normal fluctuation of heart rate 
is respiratory arrhythmia, baroreceptor  reflex, thermoregulation and 
circadian rhythm.  
 
  This HRV is a normal physiological phenomena and a 
healthy heart shows high variations in HRV. Thus depending on the 
sympathovagal tone, the heart shows beat to beat variation and its 
measure in form of R- R interval is a measure of autonomic 
function. A reduced heart rate variation indicates defective balance 
between sympathetic and parasympathetic nervous system, and the 
ability to maintain homeostasis is impaired  (Martin G. et al) 
59
. A 
reduced HRV suggests a vulnerable state in which the stress which 
may be internal or external cannot be handled.  
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Figure 2.8 Normal HRV due to Sinus Arrhythmia 
          
 
The changes in ANS is reflected in HRV, even though the 
physiological parameters lie within normal standard range. It 
identifies distress before appreciable clinical findings and reflects 
the early loss of internal homeostasis.  
 Though many factors fluctuate heart rate resting HRV 
measures the fluctuation of heart beat during respiration 
(respiratory arrhythmia). The phenomena of normal variation 
diminishes with age and also in diseased conditions.  
          HRV is considered as a marker of parasympathetic  system 
and it is proved by using parasympathetic markers  (Task forces)
60
. 
It is a non- invasive tests which helps in evaluation of the ANS and 
its integral functions.  
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HRV measurement: 
 The simplest method of evaluation of HRV is time domain 
measures. At a given point of time the heart rate and the interval 
within the successive beats is determined by time domain values.  
In a continuous ECG record, each of the QRS complex is 
identified and all the intervals between consecutive QRS complex is 
determined. That interval is called as Normal- Normal (NN) 
intervals, by which the instantaneous heart rate is determined. The 
commonly used simple time domain factors are mean NN interval, 
mean heart rate and Standard Deviation of NN (SDNN).  
SDNN is the square root of  variance and it represents the total 
power of the spectral analysis. It reflects all the components which 
occur cyclically during the variability period of recording. Better 
results of SDNN is brought if the period of monitoring is long, like 
24 hour monitoring. In short duration of recording the variance of 
total HRV increases
60
. 
Power Spectrum Density Analysis:  
The information of variance (power) distribution is provided 
by power spectral density analysis. The analysis is carried by non - 
parametric methods. The advantage of non-parametric method is its 
simple algorithm in form of  Fast Fourier Transform ( FFT) and a 
high processing speed. 
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The important spectral components in short term recordings around 
2- 5 minutes is  
1. Very Low Frequency(VLF) –  0.00- 0.04Hz 
2. Low Frequency( VF) –  0.04- 0.15Hz 
3. High Frequency(HF) –  0.15- 0.4 Hz 
The measurements of VLF, LF and HF components can be in 
absolute power or in normalized units ( n.u). HF and LF is measured 
in n.u highlights the balanced and controlled behavior  of the two 
branches of ANS. 
 
Role of ANS in psoriatic skin and PsA:  
The association of nervous system and immunity is well 
established. The neural and the immunal cells communicate with 
each other by cytokines secreted by activated immune cells and by 
neurotransmitter of the neural fibers to regulate the level and 
magnitude of immune response. Thus to maintain immune 
homeostasis proper neural control is essential.  
The important mechanism responsible for this synchronization 
involves the ANS is nor -epinephrine , which acts as a messenger 
from the mind to all organ systems including immune system. The 
cytokines acts on receptors in vagus or in the sympathetic nerve 
terminals or in the CNS(Ionescu G et al)
  61
 . The CNS communicate 
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the immune cells by activating sympathetic nervous system or by 
the Hypothalamo –  Pituitary- Adrenal axis and the neuro transmitter 
is nor adrenaline or a corticosteroid respectively .( Zangeneh FZ et 
al)
62           
 
The lymphocytes express receptors which binds nor adrenaline 
and corticosteroid, so that these ligands activate intracellular 
signalling pathway and regulates the immune cells. Thus a there 
exists bidirectional communication, in which one controls over the 
other (Nance DM et al) 
63
. 
In psoriasis due the activation of immune cells there is 
excessive release of cytokines which in turn causes excess 
corticosteroid and nor adrenaline secretion to control the 
inflammation. Since the main cause of trigger is unknown and not 
eliminated, (which is genetically determined) the levels of 
sympathetic hormones are elevated. It is established that the levels 
of hormone is high and the receptors in immune cells are down 
regulated. When psoriatic patients receive β - blockers there occurs 
an exacerbation of lesions in skin and in musculoskeletal 
manifestation. The reason is the excess hormones tries to put a 
check over the activated immune cells and when the inhibition is 
gone there occurs an exacerbation  (Halevy S et al)  
64
.   
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2.4 Vascular Endothelial Growth Factor (VEGF):  
New vessel formation or neovascularization includes two 
separate components, vasculogenesis and angiogenesis. Classical 
vasculogenesis occurs during embryogenesis. The new blood vessels 
are formed from hemangioblasts of primitive mesoblastic cells. 
During vasculogenesis A primitive network of endothelial tubes are 
formed which are remodeled into circulating system. The 
endothelial tubes undergo proliferation, migration, branching and 
regression. 
Angiogenesis is a physiological process of formation of new 
blood vessels. It is different from vasculogenesis. In angiogenesis 
the blood vessel arise from pre-existing vessels. Angiogenesis may 
occur by capillary sprouting or non - sprouting of new blood vessel. 
Mature endothelial cells divide and incorporate into pre-existing 
capillaries. Angiogenesis a physiological process vi tal for growth 
and development. I t also plays vital role in wound healing and 
repair. The process of angiogenesis may also occur in pathological 
condition like diabetics, hypertension, inflammatory disease and 
malignancy and also plays an important role inflammation.  
Asahara et al
65
 described the existence of endothelial 
progenitor cells in adult human blood. Normally these progenitor 
cells reside inside the bone marrow.  These progenitor cells are 
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mobilized into circulation by the signaling cytokines or angiogenic 
growth factor signal molecules.  
Bone marrow derived endothelial progenitor cells recruit to 
the sites of angiogenesis, where they undergo multiplication and 
differentiation into mature cells, which combines and forms new 
blood vessel. But some studies says even the mature adult 
endothelial cells undergo mitotic division and they undergo 
increased and rapid divisions at the time of angiogenesis. The 
estimated surface area of human adult endothelial surface area is 
1000 m
2
. On an average of 10,000 endothelial cells one will 
undergo cell division at a given time normally. During angiogenesis 
there is accelerated range of mitosis at that site.  
Physiological angiogenesis occurs in  
 Growth and developmental period  
 Wound healing and repair  
 Repair of  corpus luteum 
 Formation of placenta 
Some examples of pathological angiogenesis  
 Tumour formation –benign and malignant 
 Senile macular degeneration of eye 
 Endometriosis 
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 Tumour metastasis 
 Inflammatory conditions like psoriasis, rheumatoid arthritis  
 Diabetes  
 Hypertension 
  Angiogenesis is controlled by both activators and inhibitors. 
Among the activators there exits three family of activators and their 
receptors are also included.  
1. VEGF/ VEGF Receptor – the most studied family of 
angiogenesis activator 
2. Angiopoietin / Tie system –  important in vessel maturation 
and quiescence of endothelial cells.  
3. eph/ Ephrin system- positional guidance cues and arterio 
venous asymmetry. 
Acidic and basic Fibroblast Growth Factor and many others also 
aids in angiogenesis but are included in the family of angiogenesis 
inducers. 
Vascular Endothelial Growth Factor (VEGF) family includes five 
members and they play important role in angiogenesis, 
vasculogenesis and also lymphogenesis.  
The members of VEGF family are 
1. VEGF A or simply VEGF 
2. VEGF B 
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3. VEGF C 
4. VEGF D 
5. Placental Growth Factor (PlGF) 
All these are proteins that contains signal sequence that is 
cleaved during biosynthesis. Splicing of their mRNA creates 
multiple isoforms. Multiple isoforms exists especially to VEGF, 
VEGF B, PlGF. There are three receptors which are protein kinases 
dependent and they are VEGF R1, VEGF R2, and VEGF R3. Two 
non- enzymatic receptors is also present which is Neurophilin 1 and 
Neuropilin 2. The Neurophilins are receptors involved in neuronal 
development. The form receptors for semaphorins, which a re 
molecules involved in axonal guidance  (Kolodkin AL et al) 
66
.Many 
cytokines induce the expression of VEGF in cells and they are 
Platelet- Derived Growth Factor, fibroblast growth factor and 
Transforming Growth Factor(Ferrara N et al)
67
. 
 
Discovery of VEGF 
Senger et al
68
 in 1983 isolated VEGF from ascites protein and 
found to induce angiogenesis in cell culture. This factor which was 
named as VEGF later was found to cause increased permeability.  
Ferrara and Henzel
67  
purified this protein from bovine cells and 
found to enchase vascular endothelial mitogenic property  
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(Gospodarowicz Det al)
 69
.  Connolly et al
70
 isolated and purified 
this factor from guinea pig carcinoma of liver and proved its 
vascular permeability enhancing activity. VEGF is specific in 
enhancing mitosis of endothelial cells and fails to cause mitosis of 
smooth muscle cells, fibroblasts, lymphocytes, chondrocytes and 
melanocytes. Molecular weight of VEGF was estimated by 
denaturing gel electrophoresis. The molecular weight under non- 
reducing conditions is 46kDa and under reducing conditions was 
23kDa. The molecular weight shows slight variation because of N - 
glycosylation, partial proteolysis and isoforms due to alternate pre - 
mRNA splicing. It was thought as permeability factor as it increase 
the permeability of vascular endothelium by forming intercellular 
gaps, vacuoles, vesico- vascular organelles and fenestrations.  
 
Functions of VEGF 
 The first and important function of VEGF is angiogenesis. 
It aids in angiogenesis by 
1. Increased migration of endothelial cells  
2. Increase in mitosis of endothelial cells  
3. Increase in Matrix Metallo Proteinase activity .  It induces the 
expression of proteases implicated in pericullar matrix 
degradation during neo vascularization (Pepper MS et al)
71
.  
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4. Increase in αvβ3 activity. It is an integrin acts a receptor for 
phagocytosis and the phagocytic cells are macrophages and 
dentritic cells. 
5. Creation of lumen in the new blood vessel, by resorption and 
regression. 
6. It is a survival factor for endothelial cells.  
7. It increases the permeability of endothelial cells to plasma and 
plasma proteins. This action is essential in neovascularization 
and it happens without any damage to endothelial cells, with 
preserved integrity.  
 Another important function of VEGF is chemotaxic to 
macrophages and granulocytes.  
 VEGF also causes vasodilation by induction of endothelial 
Nitric Oxide Synthase ( e-NOS) and causes  release of nitric 
oxide from the endothelial cells.  
 VEGF provokes Hematopioetic Stem Cell mobilization from 
bone marrow. 
 It induces osteoblast mediated new bone formation  (Ferrara et 
al)
72
. 
 VEGF also plays role in neuronal protection  (Storkebaum et 
al) 
73
. 
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Structure of VEGF:  
  VEGF is a protein molecule and the size varies and major 
protein size is 21 kDa. The chromosomal loca tion of VEGF is on 
short arm of 6
th
 chromosome and the locus is 6 p 23(Wei MH et 
al)
74
. The splice variants for VEGF are 121, 145, 165, 183, 189 and 
206. Of these splice variants 165, 183, 189 and 165 binds to 
Heparan Sulphate Proteoglycans. The major mRNA transcript sizes 
are 3.7 and 4.5.  
 The expression of VEGF is seen first in anterior portion of 
embryo of mouse. VEGF directs the migration of cells showing 
receptors for VEGF- R1 and VEGF- R2.  The largest human 
precursor VEGF protein contains 232 aminoacids. A signal 
sequence contains 26 residues which on removal yields a mature 
protein containing 206 aminoacids. There are at least six isoforms 
of VEGF, showing variable amino acid number which  are produced 
due to alternate pre mRNA splicing . 
1)*VEGF121- shows relatively free diffusing among tissues 
2) VEGF 145 
3)*VEGF 165 –partially bound to Heparan Sulfate ProteoGlycans 
(HSPGs)  
4) VEGF 183 
5)VEGF 183 
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6)*VEGF 189 completely sequestered by HSPGs making them a 
reservoir of VEGF which can be mobilized by proteolysis in the 
ECF. 
*These are the predominant form secreted by most cells.  
Muller et al
75
 studied the structure of human VEGF using X- 
ray crystallographic structure. It contains antiparallel homodimer 
covalently by two sulfide brides which bridges between cysteine 51 
and cysteine 60. The predominant feature of each monomer is the 
cysteine knot motif. This cysteine knot motif consists of a ring of 
eight residues formed by di- sulfide bridges. 
 
Hypoxia and VEGF: 
Hypoxia a potent inducer of VEGF and it induces via Hypoxia 
Inducible Factor (HIF) which is a regulatory element of VEGF gene. 
Degradation of HIF is inhibited in hypoxia and HIF prolyl 
hydroxylases are stabilized and hetreodimerizationof  HIF occurs. It 
is called as Aryl Hydrocarbon Nuclear Translocator (ARNT). All 
these complex components bind to Hypoxia Responsive Element 
(HREs) and intiate transcription of many genes of which VEGF 
AND VEGF R1 gene are important and aids in angiogenesis to 
overcome hypoxia(Yuxiang Liu,etal)
76
. 
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VEGF in Psoriasis 
There are many first messengers in angiogenesis, including 
cytokines, but the role of VEGF is very important in psoriasis. 
Psoriasis is an immune mediated hyperproliferative  disease of 
epidermis. The hyper proliferative epidermis is supported by 
increased dermal angiogenesis and there is over expression of 
VEGF in seen in the dermal vessels. A genetic experiment on mice 
showing over expression of murine VEGF is conducted. The  mice 
showed typical features of psoriasis. Histologically it shows poor 
differentiation of epidermis, dermal thickening, increased density 
and thickening of dermal blood vessels and venulization of 
capillaries. These are classical psoriatic features.   
 
Figure 2.9 Increased Angiogenesis in Psoriatic skin  
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VEGF in PsA 
 Similar to skin findings VEGF is over expressed at the site of 
inflammatory joints and soft tissues, tendons. VEGF levels in 
synovium of affected joints is increased and these levels are 
reflected in the serum. In PsA the levels of serum VEGF also 
reflects the disease activity. Serum VEGF is also elevated in 
Rheumatoid arthritis and in SLE.  
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                                 AIM AND OBJECTIVES 
 
AIM  
To study and compare the autonomic nervous system (ANS) 
functions and serum Vascular Endothelial Growth Factor (VEGF) in 
psoriatic skin and psoriatic arthritis (PsA) patients.  
 
OBJECTIVES 
1) To study the ANS functions of psoriatic skin and PsA patients.  
2) To compare the ANS functions between psoriatic skin and PsA 
patients. 
3) To study the level of serum VEGF levels in psoriatic skin and 
PsA patients.  
4) To compare the serum VEGF levels in psoriatic skin and PsA 
patients. 
5) To correlate the serum VEGF levels and ANS function in 
psoriatic skin and psoriatic arthritis patients.  
6) To evaluate the role of ANS function and serum VEGF levels 
in the pathogenesis psoriatic skin and psoriatic arthritis.  
7) To determine the role of ANS and serum VEGF levels in 
progression of psoriatic skin disease into PsA.  
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MATERIALS AND METHOD 
 
The study is conducted in the Institute of Physiology and 
Experimental medicine, Madras Medical College, Chennai,  in the 
Department of Dermatology and in the Department of 
Rheumatology, Government Rajiv Gandhi Hospital,  Chennai.  The 
study is conducted only after the approval of Institutional Ethical 
Committee. 
The study contains three groups - controls, psoriatic skin and 
psoriatic arthritis patients. All the three groups contain age and sex 
matched individuals to avoid bias caused by age and sex. The 
duration of study is  five months from May 2014 –  September2014.  
 
4.1 Selection of cases: 
 Fifteen male and fifteen females are randomly selected in each 
group and the age of the individuals should lie between 20 - 40 
years. In psoriatic skin disease the diagnosis is based on clinical 
presentation, and the signs and symptoms. There is no separate  
criteria for diagnosis of the disease and biopsy is not necessary. In 
the PsA group the CASPER criteria is used for the diagnosis. The 
disease shows no sexual predilection and male, female ratio is 1:1 
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and hence the study group contains equal number of ma le and 
female.   
Inclusion criteria for psoriatic skin patient 
1) Age group between 20- 40 years  
2) Clinical evidence of psoriatic lesions, which may be of any 
severity 
3) The lesions may be new or old or healing  
4) Newly diagnosed or a chronic patient with or without 
treatment 
5) The disease may be in remission, exacerbation or a chronic 
form 
Exclusion criteria for psoriatic skin patient group  
1) Presence of arthritis or evidence of musculoskeletal symptoms 
in form of myalgia, enthesitis  
2) Presence of infection 
3) Pregnancy or postpartum period 
4) Diabetes, hypertension, malignancy 
5) Established coronary heart disease 
6) Renal failure 
7) Hepatitis 
8) Evidence of interstitial lung disease  
9) Presence of any other ill effects due to prolonged medications.  
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Inclusion criteria for PsA group: 
1) Age 20- 40 years 
2)  Seronegative  arthrit is satisfying CASPER criteria 
3) PsA of any subtype according to Moll and Wright 
classification 
4) Presence of skin or nail psoriasis with arthritis  
5) Absence of skin disease but fits in CASPER criteria  
6) Newly diagnosed, or a chronic disease  
7) The disease may be in remission or in acute exacerbation  
 
Exclusion criteria for PsA group:  
1) Presence of infections 
2) Pregnancy or postpartum period 
3) Presence of other chronic illness like hypertension, diabetes, 
hepatic or renal disease 
4) Presence of malignancy 
5) Coronary Heart Disease 
Thirty individuals in each group satisfying these criteria is included 
in the corresponding group. 
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Selection of controls 
 Fifteen male and female healthy individuals without any acute 
or chronic disease like infections, hypertension, diabetes, CHD, 
malignancy, hepatic renal or lung disorders. 
  
 Before the study the participants should be informed about the 
purpose of study and the procedure is explained. An informed 
consent is obtained from both the study and the con trol groups. 
Detailed history is elicited and complete examination including the 
general and systemic examination is performed. Under aseptic 
conditions blood samples are collected and stored under -20
0
 C. 
Since the study period is 5-6 months and the blood samples has to 
stored properly. All the participants should undergo a battery of 
ANS function tests.  
4.2 Study design: 
Case control study 
 
4.3 Materials essential for ANS function tests:  
 INCO Niviqure Ambulatory Digital ECG recorder.  
 Sphygmomanometers  
 Hand grip dynamometer  
 4-60C water in a basin 
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4.3.1 Description of the Instrument 
 The instrument is INCO NiviqureAmbulatory Digital ECG 
Recorder, which is a multi-load,solid state standalone digitalized 
and computerized recording system. It acquires and analyses and 
also stores the ECG data over a long period.  
 
The data acquired is stored in flash memory then it is later can 
be downloaded and analysed. The data is transferred from the 
memory module to the computer through a compatible module 
which is an interface RS233C. 
 
         This instrument has powerful processing software for online 
ECG study, off line data replay, data storage and data study and 
transfer to other statistical software analysis and also FFT analysis.  
 
 Thus the ECG data is initially recorded in the INCO Niviqure  
Ambulatory Digital ECG Recorder and then transferred to the 
computer system and the data is processed by eliminating the 
artefacts and the selected segment is analysed for HRV. 
  The following flow chart gives the summary of each steps 
used for recording and processing the ECG data for the analysis of 
HRV. 
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Figure 4.1 
 
4.4 Methodology 
All the ninety control and study groups are subjected to 
resting heart rate variability and a series of ANS function tests .  
The ANS function tests include changes in HRV and blood pressure 
when subjected to some physiological manoeuvres.   
 There are many internal and external factors can affect the 
result of ANS functions. These are the following precautions to be 
taken while performing the ANS function tests.  
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 The individuals should be comfortable, relaxed, relived from 
anxiety without any painful events.  
 The ANS function tests should be carried preferably in the 
morning (8AM- 12 AM) after breakfast.  
 Any compressive garments causing discomfort should be 
avoided. 
 Drugs altering ANS should not be used.  
 The subjects should avoid coffee, tea, cigarettes, alcohol 
before the tests 
 The bladder should be empty before the test.  
 The test should be performed in a quiet, slightly dark room 
with a controlled and comfortable temperature.  
 Mobile phones and other electronic gadgets should be removed 
and placed at least 5 feet away from the subject.  
 The subjects are instructed about the various procedures and 
allowed to practice the manoeuvers.  
 The electrodes should be placed in the following positions  
 
The exploring electrodes should be placed in the left and right 
subclavicular position in the mid clavicular  line. The last exploring 
electrode should be in the middle of left sub costal region. The 
reference electrode should be in the right subcostal region.  
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  The period of rest should be around 30 minutes during 
which the 10 minute resting HRV is recorded cont inuously. After 
recording ECG for 10 minutes , continuous 5 minute (320 s) is 
selected for short term ECG analysis.  
 
The ECG data is screened for artefact and then edited. The 
data is fed to the software of HRV analysis.The digital converter 
analogue of resting ECG data is done by using AD converter. The 
sampling frequency is kept as 1024/ s. the converted ECG data is 
analysed by power spectrum using Fast Fourier Transformation 
(FFT). Mean Heart Rate, SDNN, normalized Low Frequency 
(nLF), normalized High Frequency(nHF), and LF/HF ratio is 
estimated. 
 
4.5 Deep breathing: 
Respiratory arrhythmia is the basic principle behind the tests. 
To make the respiratory arrhythmia most prominent the respiratory 
rate should be 6/minute. The individual should breathe at a  rate of 
5s for inspiration and 5s for expiration.  The average acceleration 
during inspiration and average deceleration during expiration is 
calculated. The difference between them is calculated as E/I ratio.  
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The acceleration and deceleration is calculated by the RR 
interval during inspiration and expiration.  
This deep breathing procedure evaluates the parasympathetic 
nervous system integrity. 
 
Procedure: 
 The subject should be comfortable and the minimum of 15 
minutes of rest should be given between the various ANS tests. The 
inspiration and expiration should be slow and last for 5s.A 
minimum of 6 cycles should be performed  
 
 
 
 
 
The results depend on age, sex, body procedure and drugs.  
4.6. Valsalva manoeuvre: 
This procedure evaluates the functioning of baroreceptors. It 
is a forced voluntary expiration of the subject against a resistance.  
It consists of four phases.  
PhaseI-  Increase in transthoracic pressure, transient increase in 
blood pressure and fall in heart rate.  
E/I Ratio = Longest RR interval during expiration/  
                    Shortest RR interval during inspiration 
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Phase II- Reduced venous return resulting in low stroke volume, 
ultimately ends in reduced blood pressure and compensatory 
tachycardia. 
Phase III- End of expiration resulting in further reduced blood 
pressure due to pulmonary vascular expansion and heart rate 
increases. 
Phase IV–Baroreceptor activation, abrupt raise in blood pressure 
above the resting value and the concomitant bradycardia occurs.  
 
 
Procedure: 
The precautions are same as that of the previous test.  The ECG 
should be recorded from the resting period throughout the 
procedure. The subject is asked to blow into a mercury manometer 
to maintain a column of mercury at 40mmHg for 15s. The results of 
the test relay on proper performance of the manoeuvre, ag e, sex, 
body positions and drugs.  
4.7. Cold Pressor Test (CPT): 
 Immersion of hand or feet inside the cold water (4
0
) for 60- 90 
seconds cause activation of sympathetic system via afferent pain 
and temperature fibres of skin. There is a raise in diastolic blood 
pressure which is a measure of sympathetic activity.  
Valsalva Ratio = longest RR interval/ shortest RR interval 
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Procedure: 
All the precautions should be taken similar to the other tests. 
One hand of the subject is immersed inside the cold water.  The 
blood pressure should be measured on the opposite hand after 90s of 
immersion. The result is presented as difference between the 
procedure blood pressure and the resting bloodpressure.  
4.8 Isometric Hand Grip: 
 When the subject is isometrically pressing a hand grip 
dynamometer using 1/3
rd
 of maximal strength for 3-5 minutes, there 
is raise in diastolic pressure.  The elevated diastolic pressure is due 
to cardiac acceleration without increase in peripheral vascular 
resistance.  
Procedure: 
After a period of rest the subject is asked to press  the 
isometric hand grip upto the maximal power. Then the subject is 
instructed to maintain 1/3
rd
 of maximal capacity for three minutes 
and the raise in diastolic blood pressure is noted.  
4.9 orthostatic test:  
 After a period of rest in supine position,  the subject assumes 
an upright position, there occurs hemodynamic changes. These 
changes measure the activity of baroreceptors and ultimately 
measure the activity of both sympathetic and parasympathetic 
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activity. After assuming an upright position there is pooling of 
blood in the lower limbs, decrease in venous return and stroke 
volume and it initiates a compensatory mechanism.  
Immediate response occurs in 1-2 min, abrupt fall in blood pressure 
and acceleration of heart rate. 
The heart rate changes are measured at 30
th
 and the 15
th
 beat. There 
is   an initial fall in heart rate at 15
th
 beat after standing and there is 
an increase at 30
th
 beat. 
 
 
  
PROCEDURE: 
After a period of rest around 10 minutes in supine positon, the 
subject is allowed to stand immediately without any support and 
using both the legs equally and the ECG changes are recorded.  
 
ASSESSMENT OF SERUM VEGF: 
Serum VEGF levels are assessed by VEGF ELISA (Enzyme-Linked 
Immunosorbent Assay) kit is an in vitro enzyme-linked 
immunosorbent assay for the quantitative measurement of human 
VEGF in serum. This assay employs an antibody specific for human 
VEGF coated on a 96-well plate. Standards and samples are pipetted 
30/15= RR Interval at 30
th
 beat/ RR interval at 15
th
 beat 
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into the wells and VEGF present in a sample is bound to the wells 
by the immobilized antibody. The wells are washed and biotinylated 
anti-human VEGF antibody is added. After washing away unbound 
biotinylated antibody, HRP-conjugated streptavidin is pipetted to 
the wells. The wells are again washed, a TMB substrate solution is 
added to the wells and colour develops in proportion to the amount 
of VEGF bound. The Stop Solution changes the colour from blue to 
yellow, and the intensity of the colour is measured at 450 nm. 
Figure 4.1 
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MATERIALS REQUIRED: 
1. Microplate reader capable of measuring absorbance at 450 nm.  
2. Precision pipettes to deliver 2 μl to 1 ml volumes.  
3. Adjustable 1-25 ml pipettes for reagent preparation. 
4. 100 ml and 1 litre graduated cylinders.  
5. Absorbent paper. 
6. Distilled or deionized water.  
7. Log-log graph paper or computer and software for ELISA data 
analysis. 
8. Tubes to prepare standard or sample dilutions 
 ASSAY PROCEDURE: 
1. Prepare all reagents, samples and standards as instructed.  
1. 2. Add 100 μl standard or sample to each well. Incubate 2.5 
hours at room     temperature or overnight at 4
o
C. 
2. Add 100 μl prepared biotin antibody to each well. Incubate 1 
hour at room temperature.  
3. Add 100 μlprepared Streptavidin solution. Incubate 45 minutes 
at room temperature.  
4. Add 100 μl TMB One-Step Substrate Reagent to each well. 
Incubate 30 minutes at room temperature.  
5. Add 50μl Stop Solution to each well. Read at 450 nm 
immediately. 
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CALCULATION OF RESULTS: 
Calculate the mean absorbance for each set of duplicate 
standards, controls and samples, and subtract the average zero 
standard optical density. Plot the standard curve on log -log graph 
paper or using Sigma plot software, with standard concentration on 
the x-axis and absorbance on the y-axis. Draw the best-fit straight 
line through the standard points . 
 
All the results are calculated and mean and standard deviation 
is estimated. The data is the statistica lly analysed by using one way 
ANOVA.  
 
  The correlation between the data is assessed by Pearson’s 
correlation. 
 
The data between the two groups are assessed by unpaired student
’
s  
‘t’  test. 
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RESULTS 
 
                 The data obtained from conducting the Autonomic 
Function Tests and serum VEGF were statistically analysed using 
the Statistical Package for Social Sciences (SPSS) software version 
22. From the data, mean and standard deviation of the varia bles are 
determined for the individual three groups. One way ANOVA test 
was employed for statistical analysis.  
 
* ‘P’ value < 0.05 was considered as significant  
* ‘p’ value < 0.01 was considered as highly significant  
* ‘p’ value < 0.001 was considered as very highly significant 
 
5.1 Comparison of Age  
  In three study groups, age is compared and the results along 
with ANOVA is shown in table 5.1. The mean age of control group 
is 30.17± 6.6, and that of Psoriatic skin patient’s group and 
Psoriatic arthritis  patient
’
s group is 30.13±5.98, 31.13±5.56 
respectively. The difference between the age group is found to be 
statistically not significant.  
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Study  
groups 
Mean 
Age 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
 
Control 
 
30.17 
 
6.6                    
 
Between 
groups 
 
 
2 
 
19.23 
 
9.62 
 
 
 
 
 
0.262 
 
 
 
0.77 Psoriatic 
skin 
 
30.13 
 
5.98 
 
 
 
 
 
Within  
Groups  
 
87 
 
3183.36 
 
36.59 
Psoriatic 
arthritis  
31.13 5.56 
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5.2 Comparison of resting blood pressure:  
The resting systolic and diastolic blood pressure of the study was 
measured and statistically analysed and the results are shown in 
table 5.2. The resting systolic blood pressure was found to be 
statistically highly significant (p value 0.001) and that of dias tolic 
blood pressure is statistically not significant (p value 0.85)  
Table 5.2 
Study  
groups 
Mean  S 
BP 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
 
Control 
 
123.2 
 
481                    
 
Between 
groups 
 
 
2 
 
491.29 
 
245.64 
 
 
 
 
 
11.8 
 
 
 
0.001 Psoriatic 
skin 
 
127.67 
 
4.93 
 
 
 
 
 
Within  
Groups  
 
87 
 
1803.41 
 
20.728 
Psoriatic 
arthritis  
128.20 3.84 
 
Study  
groups 
Mean 
D BP 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
 
Control 
 
79.05 
 
2.97                    
 
Between 
groups 
 
 
2 
 
78.7 
 
39.36 
 
 
 
 
2.56 
 
 
 
0.85 Psoriatic 
skin 
 
79.73 
 
2.96 
 
 
 
 
 
Within  
groups  
 
87 
 
1336.63 
 
15.36 
Psoriatic 
arthritis  
81.43 5.56 
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5.3 Comparison of Mean Heart Rate time domain variable:  
The mean heart rate of the study groups is calculated from resting 
Heart rate   variability statistically time domain analysis. The 
results are mentioned in    
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Table 5.3. The results show there is no statistical significance 
between the three groups and the ‘p’ value is  0.335 
Table5.3 
Study  
groups 
Mean 
HR 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 73.40 5.18  
Between 
groups 
 
 
2 
 
45.75 
 
22.88 
 
 
 
 
 
1.10 
 
 
 
0.335 
Psoriatic 
skin 
 
75.07 
 
3.59 
 
 
 
 
 
Within  
Groups  
 
87 
 
1800.71 
 
20.70 
Psoriatic 
arthritis  
 
74.33 
 
4.73 
 
 5.4 Comparison of SDNN values:  
                  The time domain value SDNN for control is 59.80± 
16.24, and that for skin and arthritis patients is 47.50± 10.30 and 
49.50± 10.30 respectively. The statistical analyse of the data 
showed no clinical significance (‘p’ value 0.7)  
Table 5.4 
Study  
groups 
Mean 
30/15 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 59.80 16.2                  
Between 
groups 
 
 
2 
 
2613.8 
 
1306.9 
 
 
 
 
 
6.7 
 
 
 
0.7 
Psoriatic 
skin 
 
47.50 
 
10.3 
 
 
 
 
 
Within  
Groups  
 
87 
 
16888.4 
 
194.12 
Psoriatic 
arthritis  
 
49.5 
 
10.3 
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5.4 Comparison of resting Heart Rate Variability frequency 
domain variables: 
                The frequency domain values of the study groups and 
their statistically significance was shown table 5.4. The LF 
normalised units (nu) which is a sympathetic tone indicator is 
higher in psoriatic skin and PsA patients. The HF normalised uni ts 
an indicator of parasympathetic tone is significantly reduced in 
psoriatic skin and PsA patients. The ratio between LF and HF is an 
indicator of sympathovagal balance and it is significantly higher in 
the psoriatic skin and PsA patients suggesting an au tonomic 
dysfunction. 
Table5.5 
Study  
groups 
Mean 
nLF 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 48.07 7.70                  
Between 
groups  
 
2 
 
 
5652.07 
 
 
2826 
 
 
 
71.94 
 
 
0.000 
Psoriatic 
skin 
 
59.36 
 
5.16 
 
Within  
Groups  
 
87 
 
3417.30 
 
39.24 Psoriatic 
arthritis  
67.39 5.65 
 
Study  
groups 
Mean 
n HF 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 51.93 7.7                  
Between 
groups 
 
 
2 
 
 
 
5652 
 
 
 
2826 
 
 
 
 
 
71.94 
 
 
 
0.000 
Psoriatic 
skin 
 
40.64 
 
5.65 
 
Within  
Groups  
 
87 
 
3417.3 
 
39.27 
Psoriatic 
arthritis  
 
32.61 
 
5.16 
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Study  
groups 
Mean 
LF/H
F 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 0.97 0.29  
Between 
groups 
 
 
2 
 
20.60 
 
10.29 
 
 
 
 
 
72.95 
 
 
 
0.000 
Psoriatic 
skin 
 
1.50 
 
0.33 
 
 
 
 
 
Within  
Groups  
 
87 
 
12.27 
 
0.141 
Psoriatic 
arthritis  
 
2.14 
 
0.48 
 
5.5 Comparison of autonomic function tests:  
5.5.1 Orthostatic standing:  
                  The mean ratio between the 30
th
 heart beat RR interval 
and the 15
th
 heart beat RR interval during orthostatic test between 
the study groups is calculated and statistically analysed and the 
results shows very high significance (table  5.5) . 
Table5.6  
Study  
groups 
Mean 
30/15 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 1.14 0.04  
Between 
groups 
 
 
2 
 
1.374 
 
0.687 
 
 
 
 
 
66.79 
 
 
 
0.000 
Psoriatic 
skin 
 
1.07 
 
0.08 
 
 
 
 
 
Within  
Groups  
 
87 
 
0.8947 
 
0.016 
Psoriatic 
arthritis  
 
0.85 
 
0.15 
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5.5.2Cold pressor test: 
               The diastolic pressure is measured at 1 minute and 5 
minute after immersing hand in cold water at 10 C and the results 
are shown in table 5.6. The results are statistically analysed and 
found to very highly significant.  
Table 5.7 
Study  
groups 
Mean 
1mt 
DBP 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 6.56 2.11                 
Between 
groups 
 
 
2 
 
 
 
206.43 
 
 
 
103.2 
 
 
 
 
 
25 
 
 
 
0.000 
Psoriatic 
skin 
 
9 
 
2.1 
 
Within  
Groups  
 
87 
 
357.3 
 
4.1 
Psoriatic 
arthritis  
 
10.2 
 
1.86 
 
5.5.3.Isometric Hand Grip test:  
                The diastolic blood pressure is measured at 1minute and 
five minute after subjecting to 30% of maximum voluntary 
contraction to all the individuals in all the three study groups and 
the results were analysed statistically, show in 5.7. The result 
shows very high significance in one minute diastolic blood pressure  
(‘p’ value 003) and significant value in five minute diastolic blood 
pressure (‘p’ value 0.04).  
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Table 5.8 
Study  
groups 
Mean 
1mt 
DBP 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control  2.13                
Between 
groups 
 
 
2 
 
 
 
 46.7 
 
 
 
66.389 
 
 
 
 
 
5.99 
 
 
 
 
0.003 
Psoriatic 
skin 
 
9.30 
 
1.7 
 
Within  
Groups  
 
87 
 
338.89 
 
3.90 
Psoriatic 
arthritis  
 
9.27 
 
2.08 
 
5.5.4.Deep Breathing: 
                The mean and standard deviation of E/I ratio of control 
group is 1.16±0.04 and that of psoriatic skin patients and PsA 
patients are 1.12±0.04 and 1.09±o.04 respectively (Table5.8). The 
results are statistically analysed using ANOVA and found to be 
statistically very highly significant (‘p’ 0.000)  
Table 5.9 
Study  
groups 
Mean 
E / I 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 1.22 0.06               
Between 
groups 
 
 
2 
 
 
 
 0.258 
 
 
 
0.129 
 
 
 
 
50.25 
 
 
 
 
0.000 
Psoriatic 
skin 
 
1.14 
 
0.05 
 
Within  
Groups  
 
87 
 
0.223 
 
0.0026 
Psoriatic 
arthritis  
 
1.09 
 
0.04 
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5.5.5 Valsalva ratio: 
                 The Valsalva ratio is calculated for the study groups and 
the mean and standard deviation for control is 1.26±0.05. The mean 
and standard deviation of psoriatic skin and PsA is found to be 
reduced than the control group and the values are 1.19±0.10 and 
1.10±0.04 respectively. The values are statistically analysed and 
found to be very highly significant and shown in table 5.8.  
Table 5.9 
Study  
groups 
Mean 
V/ R 
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 1.26 0.05              
Between 
groups 
 
 
2 
 
 
 
 0.402 
 
 
 
0.201 
 
 
 
 
46.03 
 
 
 
 
0.000 
Psoriatic 
skin 
 
1.21 
 
0.09 
 
Within  
Groups  
 
87 
 
0.38 
 
0.043 
Psoriatic 
arthritis  
 
1.10 
 
0.05 
 
5.6 Serum VEGF: 
         The serum VEGF levels are found to be very high in psoriatic 
skin patient and PsA patient and the values in comparison with 
controls are found to statistically highly significant (table5.9)  
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Table 5.10 
Study  
groups 
Mean 
VEGF  
SD Source of 
variation 
Df Sum of 
squares 
Mean 
square 
F 
value 
‘p’ 
value 
Control 309.8 0.05               
Between 
groups 
 
 
2 
 
 
 
 64109700 
 
 
 
32054900 
 
 
 
 
4.56 
 
 
 
 
0.01 
Psoriatic 
skin 
 
2180 
 
3298 
 
Within  
groups  
 
87 
 
610664000 
 
7019130 
Psoriatic 
arthritis  
 
2008 
 
3124 
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5.11Comparison of serum VEGF levels and age, resting blood 
pressure and mean heart rate and sympathovagal balance in 
control subjects: 
Table 5.11. 
VEGF Age Rest 
SBP 
Rest DBP Mean HR nLF nHF nLF/nHF 
    R -0.02 -0.1843 -0.267 -0.0204 0.191 -0.19 0.22 
r –  Pearson’s correlation coefficient  
               The Pearson’s correlation coefficient states that there is 
weak negative correlation between VEGF and the parameters age, 
resting blood pressure and mean heart rate shows slight negative 
correlation, which is not statistically significant in  control subjects. 
The frequency domain values and serum VEGF shows weak 
correlation which is not statistically significant in control subjects.  
 
5.12Comparison of serum VEGF levels and age, resting blood 
pressure and mean heart rate and sympathovagal  balance in 
psoriatic skin patients:  
Table 5.12. 
VEGF Age Rest SBP Rest DBP Mean HR nLF nHF nLF/nHF 
    R -0.17 -0.112 0.0023 -0.0594 0.086 -0.086 0.0836 
r –  Pearson’s correlation coefficient  
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  The Pearson’s correlation coefficient of psoriatic skin patient 
group states that there is very weak negative correlation between 
VEGF and the parameters age, resting systolic blood pressure and 
mean heart rate shows slight negative correlation, which is not 
statistically significant. The frequency domain values (nLF and 
LF/HF) and serum VEGF shows weak positive correlation which is 
not statistically significant in control subjects. The HF and serum 
VEGF shows weak negative correlation and again it is statistically 
not significant.   
 
5.13 Comparison of serum VEGF levels and age, resting blood 
pressure and mean heart rate and sympathovagal balance in PsA 
patient group: 
Table 5.13. 
VEGF Age Rest SBP Rest DBP Mean HR nLF nHF nLF/n
HF 
    R 0.041 0.0368 0.0848 0.3239 0.129 -0.129 0.213 
r –  Pearson’s correlation coefficient 
The Pearson’s correlation coefficient of PsA group states that there 
is very weak positive correlation between VEGF and the parameters 
age, resting blood pressure, mean heart rate, LF, and LF, HF ratio 
shows weak positive correlation, which is not statistically 
significant. The frequency domain values LF and serum VEGF 
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shows weak negative correlation which is not statistically 
significant PsA subjects.   
 
Comparison of sympathovagal balance and serum VEGF 
between Psoriatic skin and PsA patients:  
The normalized LF, HF ratio and serum VEGF values are 
statistically analysed by unpaired student
’s ‘t’ test between 
Psoriatic skin and PsA patients and the results are shown in table 
5.14. The LF, HF ratio shows high statistical significance (‘p’ value 
0.000) and serum VEGF shows no significance (‘p’ value 0.8)  
Table 5.14.  
 
     Variables 
                    Mean ± SD  
      ‘p’ value  Psoriatic Skin     PsA 
  LF / HF   1.50 ± 0.33 2.14 ± 0.48         0.000* 
Serum VEGF  2180.7± 3298 2008± 3124         0.8 
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DISCUSSION 
 
               The objective of the study is to assess the serum VEGF 
levels and evaluate the Autonomic Nervous System (ANS) in 
psoriatic skin and psoriatic arthritis patients and compare it 
between them. By assessing and comparing the ANS function and 
serum VEGF levels, the etiopathogenesis can be studied and the 
difference or similarity of the etiopathogenesis between the two 
forms of same disease can be identified. The integrity of 
sympathetic and parasympathetic components of ANS and the 
sympathovagal balance is assessed by standard tests like  
 Resting HRV 
 Orthostatic standing 
 Cold pressor test 
 Isometric hand grip 
 Deep breathing  
 Valsalva manoeuvre 
6.1 Comparison of Age: 
                 The age of individuals in all the three study group lies 
between 20-40 years to lighten the age related ANS changes. The 
mean age of control is 30.17± 6.6, and that of Psoriatic skin patient 
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and Psoriatic arthritis patient is 30.13±5.98, 31.13±5.56 
respectively.  The variability measured from the data between the 
groups showed variance and that is not due to the difference in age 
between the groups. One way ANOVA of age data between the three 
groups shows no statistical significance (‘p’ va lue 0.77). 
 
6.2 Comparison of sex: 
                Psoriatic skin disease shows no sexual predilection and 
the male female ratio is 1:1(Parisi R, et al)
77
.The subtypes of PsA 
may show slight male or female predilection, but as a whole the 
prevalence of the disease is equal in male and female similar to the 
skin disease(Prasad P etal)
76
 . In order to avoid bias due to sex 
variation of ANS functions and serum VEGF levels, equal number 
of male and female subjects are taken for the study. Each study 
group contains 15 male and 15 female individuals.  
 
6.3 Comparison of resting blood pressure:  
  Those individuals who are a known hypertensive, are not 
included in the study since the hypertensive subject shows altered 
ANS functions.(Julius .s et al)
77
 and elevated serum VEGF levels.  
The resting systolic and diastolic blood pressure data is collected 
from the study groups. Though the mean systolic blood pressure lies 
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within normal range (120-140mmHg) in all the three groups, the 
observed value shows increased systolic pressure in both psoriatic 
skin (127.67± 4.81) and PsA (128.20± 3.84) than 
controls(123±4.81). The difference is also statistically highly 
significant, ‘p’ value is 0.001. Similarly the resting diastolic blood 
pressure is higher in psoriatic skin (80.47±2.81) and in PsA patients 
(81.93± 2.70) than controls (79.87±2.97). Though the difference is 
not statistically significant (‘p’ value 0.85) there is an elevation of 
diastolic blood pressure also. 
In psoriatic skin disease there are series of linked cellular 
changes in skin which may be systemic in due course of time, and 
these changes are due T cell mediated autoimmune disease  (J 
Krueger et al)
79
. The pathogenesis of PsA is similar to psoriatic 
skin disease (Oliver FitzGerald et al)
80
. Both the disease is a T cell 
mediated autoimmune disease primarily affecting the skin or 
musculoskeletal structures or both. The autoimmune disease leads 
to endothelial dysfunction (De Simone C, et al)
81
. The main 
cytokine behind it is the TNF factor released  from T cells and other 
activated immune cells during inflammation  (B. J. Nickoloff et 
al)
82
.  
               The endothelial dysfunction is the shared pathogenesis 
between autoimmune disease and atherosclerosis. Endothelial cells 
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release both vascular contracting and vascular relaxing factors and 
the loss of balance occurs in endothelial dysfunction which results 
in hypertension (Brezinski EA et al)
83
. Though the study has 
excluded hypertensive patients the resting blood pressure of 
psoriatic skin and PsA is elevated than the normal controls, which 
eventfully ends in hypertension in due course of disease. Thus both 
psoriasis skin and psoriatic arthritis patients are in more risk to 
develop hypertension (Abrar A. and AhmetBacaksiz et al )
84,  85
.  
 
 
6.4 Comparison of resting HRV time domain values:  
                 The mean Heart Rate of the three groups is calculated 
for the 5 minutes during the recording of resting HRV and the 
values are not statistically significant. Similarly the SDNN values 
of the three groups also shows no statistical significance. The mean 
HR and SDNN is ill –defined statistical quantity, because they are 
dependent on the duration of recording period. Thus it is 
inappropriate to compare short term mean HR and SDNN.  
Asuman Bicer et al
86
 showed that SDNN and mean HR showed 
no significance between control and psoriatic skin patients. Similar 
results are obtained by Haligur BD et al
87
 also showed similar 
results in short term resting HRV. Similar results are shown in PsA 
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patients by Oliver Fitzgerald et al
80
. The time domain parameters 
mean Heart rate and SDNN yields better results in 24 hour Holter 
monitoring than short term resting HRV monitoring (Saul JP et al)
89
. 
 
6.5 Comparison of frequency domain parameters of short term 
HRV: 
A highly significant variation in frequency domain variables is 
observed in this study. The LF and HF values are altered by the 
total power changes. To minimise this effect normalized values are 
taken. In this study the nLF value is raised in psoriatic ski n and PsA 
patients. The nLF value for psoriatic skin and PsA patients are 
59.36± 5.36 and 67.39± 5.16 respectively, which is higher than that 
of control mean 48.07± 7.7. The results on statistical analysis show 
very high significance (‘p’ value 0.000).  
           The nLF component in frequency domain is considered as a 
marker of sympathetic nervous system modulator  (MallaniA et al)
90
. 
Akserlord S et al
91
 considers the component as a parameter having 
both parasympathetic (vagal) and sympathetic influences. A suman 
Bicer et al
86
 study have showed a significant increase in nLF similar 
to this study and states that there is autonomic dysfunction in 
psoriasis and it is associated with increased sympathetic component. 
Schmidt et al
92
 stated that in their study there is no significant 
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difference between LF component between control and Psoriasis 
skin group. 
It is an established fact that skin is a part of neuro –  endocrine 
and immune organ whose functions are governed by central 
regulatory systems (Barland et al)
93
. The concentration of β 2 
receptors in skin contribute to epidermal homeostasis and it is 
partly governed the ANS and immune system. The release of 
neurotransmitter from adrenergic nerve terminals regulates the 
magnitude of adaptive immune responses. The immune cells are 
governed locally as well as systemically by the catecholamines via 
the expression of adrenergic receptors  (Schallreuter KU et al)
94
.It is 
observed that in psoriasis there is an elevated level of circulating 
catecholamines, down regulation of β2 receptors and increased 
levels of the epinephrine synthase enzyme
61
. Thus in psoriasis there 
is an over production of catecholamine and its failure to control 
innate immunity ultimately leading to sympathetic over activi ty. 
         Though the pathogenesis of PsA is similar to skin disease PsA 
has a more systemic involvement than skin disease alone. Syngle 
A
95
 et al showed that in PsA both sympathetic and parasympathetic 
dysfunction occurs. Though Rheumatoid arthritis and  PsA are 
different entities, they share some common pathophysiological 
course. Increased nLF is observed in Rheumatoid arthritis, 
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suggesting elevated cardiac sympathetic activity and the etiology  is 
said to inflammatory stress caused by the activated autoi mmune 
cells and he cytokines released by them (Dekkers JC et al)
97
. Thus 
the cause of elevated nLF in this study is result of cardiac 
sympathetic over activity caused by inflammatory stress. The 
circulating levels of catecholamine and down regulation of β 
receptors also occur in PsA. 
             The nHF component of frequency domain spectral analysis 
of HRV is considered as a major contributor o f efferent vagal 
activity. In this study the nHF mean value of psoriatic skin (40.64± 
5.65) and PsA (32.61± 5.16) is reduced than that of controls  
(51.93±7.7). The reduced value of nHF states that there is reduced 
parasympathetic activity in psoriatic skin and PsA. In PsA the para 
sympathetic activity is still more reduced than skin involvement 
alone suggesting more severe and systemic involvement of PsA. The 
reduced parasympathetic act ivity in the presence of enhanced 
sympathetic activity reflected by increased nLF is suggested as 
parasympathetic withdrawal  (Lawrence Wilson)
98.
  
  The nHF value suggest that the parasympathetic withdrawal is 
more prominent in PsA compared to psoriatic sk in. This observation 
is supported by the works of Syngle A
95
 et al suggesting that in PsA 
in there is more of para sympathetic dysfunction in comparison to 
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sympathetic over activity. The study of  Syngle A et al is 24 hour 
ECG spectral analysis by which the power spectrum of  LF 
component taken as an account of parasympathetic activity which is 
reduced in their observation. To conform para sympathetic 
dysfunction further ANS study is needed to confirm it. The mean 
nHF of psoriatic skin patients is also reduced in comparison to 
control groups suggesting parasympathetic dysfunction. 
AsumanBicer et al
86
 study suggested than in psoriasis the LF 
component is reduced in comparison to controls suggesting a 
parasympathetic dysfunction.  
The nLF/nHF ratio is considered as mirror of sympathovagal 
balance.  Thus sympathetic over activity or parasympathetic 
reduction (withdrawal) , increase the ratio. In this study the ratio is 
increased in psoriatic skin     (1.50±0.33) and PsA (2.14±0.48) in 
comparison to controls (0.97± 0.27) and this difference is found to 
be statistically highly significant. The increased ratio suggests 
dysregulation of sympathovagal balance. Syngle A et al in their 
study both sympathetic and parasympathetic dysfunction suggesting 
loss of sympathovagal balance in PsA. Haligur, Beyzan et al
98
 in 
their study suggested an increased sympathetic over activity and a 
normal parasympathetic functions in psoriasis. In AsumanBiçer et 
al
86
 studies suggested loss of sympathovagal balance in psoriasis.  
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Psoriasis is a disease showing a wide spectrum of clinical 
manifestations including skin and musculoskeletal manifestations. 
The extent of disease depends on genetic inheritance, environmental 
factors like season, infections, stress, and also the response to 
treatment. Those who have severe clinical manifestation may shows 
severe loss of sympathovagalbalance.The factor in assessment of 
the sympathovagal balance is the duration of disease.  
 
6.6 Comparison of Autonomic Functions:  
Orthostatic standing 
                        After a considerable time of rest the test subjects 
stand with both the legs equally balanced and the ratio of RR 
interval at 30
th
 beat and 15
th
 beat is calculated for all the 
individuals in all the groups. On assuming an upright position there 
is pooling of blood in extremities and reduced venous return 
resulting in reduced stroke volume. During this period there is 
acceleration of heart rate, which occurs during the first 15 seconds. 
To maintain hemodynamic parameters there occurs a compensatory 
reaction of raise in blood pressure within 30 seconds during which 
there is reduction of heart rate. Hence the ratio of RR interval 
during 30
th
 second and 15
th
 second is a measure of parasympathetic 
activity
99.  
109 
 
In this study the mean 30/15 of the control groups are 
calculated and reduced to 1.07± 0.04 in Psoriatic skin and 0.85 ± 
0.15 in PsA patients. The values are tend to be lower than controls 
(1.14± 0.04). The 30/15 is a measure of activity of baroreceptor 
function and reflects the intactness of vagal reflexes. In both form 
of psoriasis the 30/15 value is reduced, but in comparison to skin 
disease in PsA it is much more reduced. Syngle A et al
95
 in their 
study states parasympathetic disorder is most common in PsA than 
sympathetic dysfunction. In their study abnormal pseudo motor 
dysfunctions are reported. The etiology may be small fibre 
peripheral neuropathy associated with autoimmunity.  
Cholinergic innervation of sympathetic sweat glands whose 
response is reduced in PsA. Similar results are also found in 
Rheumatoid arthritis and showed improvement of pseudo motor 
functions after treatment with Disease Modifying Drugs. Haligur et 
al in their study showed normal parasympathetic functions. In this 
study the deviation of 30/15 ratio of psoriatic skin patients is less in 
comparison to PsA. 
 
Cold pressor test: 
 CPT is a test to access the sympathetic system, in which 
immersion of hands or feet in cold water around 4-6o C for 60- 90 
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seconds leads to activation of afferent temperature, pain from skin. 
The sympathetic activation causes increase in diastolic blood 
pressure without much alteration in peripheral resistance.  
             In this study it the diastolic  blood pressure in one minute 
shows an increase in both psoriatic skin (9.0±2.1) and PsA patients 
(10.20±1.86). The raise in diastolic blood pressure in controls is 
6.56± 2.11. The difference in blood pressure is found to be 
statistically highly significan t (‘p’ value 0.000). The elevated 
diastolic blood pressure is due to increased outflow of impulses 
from sympathetic nervous system due to stimulation of pain and 
cold receptors. Syngle A et al showed increased sympathetic 
activity in PsA patients and Markuszeski et al  also showed 
increased sympathetic activity in psoriatic skin patients resulting in 
elevated diastolic pressure in CPT.  
 
*Isometric Hand Grip: 
In this study there is increased raise of diastolic blood 
pressure in psoriatic skin and PsA patien ts and the raise is also 
statistically significant. The reason for this elevation is similar to 
that of CPT, and the same explanation carries well. The raise of this 
diastolic blood pressure is associated with no alteration in 
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peripheral vascular resistance along with accelerated heart rate. The 
same results are attained by Syngle A et al
95
 , Haligur B D et al
87
.  
 
*Deep breathing: 
Respiratory arrhythmia is the principle behind this test. 
During inspiration the heart rate increases and the reverse occurs in 
expiration. The ratio between the longest RR interval during 
expiration and the shortest duration during inspiration is calculat ed 
between the groups. The values are reduced in psoriatic skin and 
PsA patients and the reduction is said to statistically significant. 
Syngle A et al states in the study conducted on both PsA and RA 
suggests parasympathetic dysfunction in form of parasympathetic 
withdrawal. Similarly  
Haligur et al states that psoriatic skin disease shows 
parasympathetic withdrawal and, AsumanBicer et al showed proper 
parasympathetic functioning in psoriasis. The AsumanBicer  et al 
study includes deep breathing test and found to be reduced than 
control but the results are statistically not significant.  
*Valsalva Ratio: 
The function of baroreceptors is evaluated by the Valsalva 
manoeuvre. The VR ration is longest RR interval in  phase IV and 
the shortest interval between the phase II.  
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        The VR ratio is reduced in both psoriatic skin and PsA 
patients than the controls and the result is found to be statistically 
significant. Valsalva ratio involves both sympathetic and 
parasympathetic components and the results can be interpreted as 
autonomic dysfunction. It cannot specify which component has gone 
wrong since the change in blood pressure is not measured. To 
measure blood pressure accurately in the four phases of the 
manoeuvre is difficult manually by sphygmomanometer.  
 
6.7 Serum VEGF levels: 
The serum VEGF levels (in picograms) the skin (2180±32) and 
PsA (2008±3128) patients are found to be highly elevated than in 
controls (309± 0.05) and the result is found to be statisticall y 
significant. There are many studies to support the elevated level of 
serum VEGF in skin lesions and also in the serum (Bhushan M et 
al
100
,  Creamer D
101
). It is the major epidermis derived growth factor 
specific for vessel growth (Detmar M)
102
. It is stated that the 
presence of altered VEGF gene provides strong suspicion to develop 
psoriasis (Young HS). 
       The level of VEGF is also elevated in PsA patients and the 
result is supported by Przepiera- Bedzak H et a 
103
.It is stated in 
that study that VEGF plays an important role in pathogenesis of the 
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disease. It is also stated that VEGF levels reflect the disease 
activity
104
. 
      In this study there is variation of values between the patient 
groups and the variations are to level of severity of the disease and 
the heterogeneity nature of the disease.  
6.8Correlation of serum VEGF levels and autonomic activity:  
The serum VEGF levels are weakly associated with autonomic 
functions in all the three study groups.  Thus serum VEGF levels 
has little or no influence in the autonomic functions. They reflect 
the severity, extent of involvement, and also the response to 
treatment (Flisiak I et al)
105
. Autonomic dysfunction is an ongoing 
process may take many years to evolve. Thus the levels of 
autonomic function cannot be accessed by the serum VEGF levels.  
6.9 Comparison of serum VEGF levels between psoriasis skin 
and arthritis: 
The serum VEGF levels are elevated in both the disease 
groups and inter comparison between them using unpaired student
’
s 
‘t’ test shows no statistical significance (‘p’ value 0.8). Thus serum 
VEGF levels are elevated in both the disease and there is  no 
difference between the values.  
 
114 
 
6.10 Comparison of ANS function between Psoriatic skin and 
Psoriatic arthritis:  
The LF/HF ratio is taken to access the sympathovagal balance 
the study group. The results shows high statistical significance. In 
PsA there may be both skin and musculoskeletal involvement. PsA 
is also considered as severe form of   disease and shows 
manifestation in patients having severe skin involvement. However 
all PsA patients on a routine do not show severe skin manifestation 
clinically because of the systemic treatment taken for 
musculoskeletal disease heals the skin lesions in due course of time. 
Thus it is concluded that PsA is a severe form systemic disease. 
Both the form of disease share some same etiology and 
pathogenesis. Hence the ANS dysfunction is severe in PsA patients 
than that of psoriatic skin disease alone.   
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LIMITATIONS OF THE STUDY 
 
1. The study group is small containing only 30 individuals. The 
sample size is too small to substantiate the results.  
2. The patients in both groups are not inter classified according 
to severity, and treatment wise.  
3. The psoriatic skin patient may develop into PsA and a 
longitudinal study can assess the progression ANS dysfunction 
in them. 
4.  The role of ANS functions in such transition is no t studied. 
5. The role of duration of the disease in ANS is not defined.  
6. The wide variation of serum VEGF levels in the disease 
groups is not proved to be due to severity, the heterogeneity of 
the disease or due to the effect of treatment.  
7. The modification of ANS functions in response to treatment is 
not studied in this study. A longitudinal study may evaluate it.   
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CONCLUSION 
 
This study states that in both psoriatic skin and PsA patients 
there is reduced HRV with sympathetic over activity and 
parasympathetic withdrawal and loss of sympathovagal balance. The 
severity of the ANS dysfunction is more in PsA. In both the disease 
types sympathetic over activity predominates.  
The serum VEGF levels are elevated in both psoriatic skin and 
PsA patients. The serum VEGF levels shows no difference between 
the disease groups. 
The levels of serum VEGF has no influence over the 
autonomic functions of the patients, but acts as a inflammatory 
marker and reflects the severity of disease.   
The autonomic function tests helps to determine the autonomic 
dysfunctions earlier even before the onset of clinical findings. The 
control of disease in form of reduced inflammation may reduce the 
progression of ANS dysfunction and definitely reduce the serum 
VEGF levels.   
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For adult participants:  
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representative if  participant incompetent )  
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PROFORMA 
 
1. Name : 
2. Age: 
3. Sex: 
4. Address : 
5. Occupation : 
6. Complaints/duration: 
7. Psoriasis Area and Severity Index  
8. History and duration of joints involvement  
9. Other  associated symptoms- 
10.  Past history: 
11. History of any drug intake 
12. History of associated illness: 
a. Diabetes 
b. Hypertension 
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EXAMINATION 
 
General examination: 
Pulse rate: 
Blood pressure:  
Systemic examination: 
Cardiovascular system: 
Respiratory system: 
Gastrointestinal system: 
Central nervous system: 
 
 
 
 
 
 
 
 
 
 
 CONTROL DATA 
S. No AGE SEX 
Rest 
SBP 
REST 
DBP 
MEAN 
HR SDNN nu LF N u HF LF/HF 
OST 
30/15 
CPT 
DBP 
IHGT 
DBP E/I VR VEGF 
1 28 F 120 76 67 69 34.5 65.5 0.53 1.23 6.8 16 1.24 1.24 7.6 
2 35 F 126 82 78 55 43.2 56.8 0.76 1.13 7.8 22 1.19 1.21 538 
3 35 F 120 80 69 65 48.3 51.7 0.93 1.13 8 24 1.24 1.29 2.5 
4 23 F 118 72 70 50 48.6 51.4 0.95 1.19 4 18 1.21 1.21 4.9 
5 30 F 120 80 75 52 55.4 44.6 1.24 1.16 4.6 12 1.16 1.25 7.5 
6 24 F 120 74 78 48 49.5 50.5 0.98 1.18 8.2 14 1.22 1.32 4.6 
7 35 F 118 80 64 50 58.4 41.6 1.40 1.07 6 16 1.28 1.29 11.2 
8 25 F 120 78 71 91 34.9 65.1 0.54 1.15 4.2 10 1.22 1.27 120 
9 26 F 124 78 76 51 55.8 44.2 1.26 1.2 6.2 14 1.2 1.33 2246 
10 24 F 120 80 77 91 39.3 60.7 0.65 1.09 6.8 12 1.22 1.21 46 
11 39 F 124 80 74 49 56.4 43.6 1.29 1.15 6.4 16 1.22 1.19 7.9 
12 40 F 124 80 78 91 52.3 47.7 1.10 1.19 8 10 1.19 1.23 7.5 
13 32 F 134 78 69 51 45.4 54.6 0.83 1.12 4 16 1.34 1.32 67 
14 21 F 116 74 74 94 43.4 56.6 0.77 1.1 6 20 1.32 1.26 2234 
15 24 F 118 82 81 61 38.5 61.5 0.63 1.08 14 21 1.21 1.24 123 
16 22 M 120 80 87 37 48.4 51.6 0.94 1.15 6 10 1.24 1.32 7.9 
17 22 M 120 84 83 52 43.4 56.6 0.77 1.12 8 9 1.12 1.21 7.6 
18 23 M 120 80 72 54 45.8 54.2 0.85 1.12 4 8 1.14 1.21 34 
19 28 M 126 84 74 55 56.6 43.4 1.30 1.06 4.8 9 1.19 1.39 12.8 
20 36 M 130 84 69 65 54.4 45.6 1.19 1.12 6.4 10 1.24 1.25 73.7 
21 40 M 134 82 65 83 55.5 44.5 1.25 1.14 4 8 1.24 1.23 76 
22 24 M 120 80 68 51 61.4 38.6 1.59 1.08 8 7 1.22 1.31 2000 
23 33 M 120 84 73 65 43.3 56.7 0.76 1.18 6.4 10 1.16 1.21 120 
24 36 M 124 80 74 37 43.8 56.2 0.78 1.12 8 4 1.12 1.23 80 
25 33 M 120 84 70 65 48.4 51.6 0.94 1.16 8.4 8 1.24 1.27 7.8 
26 36 M 122 80 74 36 51.2 48.8 1.05 1.16 4 4 1.2 1.26 46 
27 32 M 128 80 72 65 34.9 65.1 0.54 1.12 6.4 6 1.34 1.32 6.3 
28 32 M 124 80 72 46 56.4 43.6 1.29 1.18 8.2 9 1.24 1.21 89 
29 40 M 130 80 78 65 56.4 43.6 1.29 1.09 4.8 8 1.24 1.26 7.8 
30 27 M 130 80 70 50 38.4 61.6 0.62 1.16 8.4 6 1.32 1.26 98 
 
PSORATIC SKIN DATA 
S. No 
AGE SEX RESTSBP 
REST 
DSP 
REST 
HR SDNN 
NU LF 
skin Nu HF LF/HF 30/15 
CPT 
DBP 1 
IHG 
DBP1 E/I R 
VR 
Ratio VEGF 
1 25 F 124 80 72 42 57.2 42.8 1.34 1.11 11 10 1.18 1.32 146 
2 32 F 130 82 78 46 56.5 43.5 1.30 1.13 9 9 1.08 1.22 189 
3 28 F 130 80 74 38 56.4 43.6 1.29 1.08 8 9 1.14 1.1 230 
4 24 F 124 80 73 46 48.6 51.4 0.95 1.14 6 5 1.2 1.25 6000 
5 34 F 140 80 76 47 65.5 34.5 1.90 1.03 15 12 1.13 1.43 178 
6 23 F 120 80 78 45 58.4 41.6 1.40 1.05 11 9 1.2 1.09 234 
7 21 F 120 70 72 39 55.5 44.5 1.25 1.1 9 6 1.11 1.21 125 
8 23 F 128 78 80 49 64 36 1.78 1.13 8 8 1.12 1.12 245 
9 38 F 134 80 72 69 59.7 40.3 1.48 1.02 9 11 1.16 1.24 6000 
10 32 F 130 84 78 54 62.3 37.7 1.65 1.01 9 10 1.12 1.12 1234 
11 40 F 130 80 71 58 64.3 35.7 1.80 1.03 11 9 1.18 1.26 6000 
12 24 F 124 76 68 37 44.7 55.3 0.81 0.9 8 9 1.21 1.22 156 
13 28 F 130 80 73 68 55.8 44.2 1.26 1.12 10 10 1.24 1.12 168 
14 38 F 126 82 76 48 62.3 37.7 1.65 1.16 6 7 1.15 1.26 95 
15 31 F 132 80 77 65 58.4 41.6 1.40 1.1 11 10 1.15 1.32 156 
16 32 M 130 86 73 43 59.8 40.2 1.49 1.15 12 11 1.09 1.24 56 
17 24 M 120 82 74 38 64.3 35.7 1.80 1.13 10 9 1.15 1.1 20144 
18 33 M 128 80 76 64 59.6 40.4 1.48 1.12 8 12 1.13 1.4 6000 
19 24 M 128 80 72 38 67.5 32.5 2.08 1.03 10 11 1.22 1.16 126 
20 23 M 124 84 78 58 62.8 37.2 1.69 1.01 5 12 1.07 1.14 6000 
21 40 M 132 80 72 65 66.7 33.3 2.00 1.08 7 8 1.13 1.24 59 
22 33 M 126 80 76 43 49.8 50.2 0.99 1.06 11 11 1.14 1.21 134 
23 30 M 124 80 82 39 52.4 47.6 1.10 1.1 7 8 1.24 1.18 129 
24 22 M 124 84 79 36 53.8 46.2 1.16 1.13 9 10 1.08 1.12 6000 
25 36 M 138 82 76 44 66.4 33.6 1.98 1.06 10 10 1.11 1.13 211 
26 40 M 128 80 80 48 58.4 41.6 1.40 1.07 7 8 1.06 1.21 54 
27 37 M 130 84 67 36 64.2 35.8 1.79 1.1 8 9 1.08 1.12 145 
28 29 M 120 80 74 37 58.8 41.2 1.43 0.8 11 10 1.03 1.24 111 
29 32 M 130 80 75 43 61.2 38.8 1.58 1.12 6 7 1.12 1.21 123 
30 28 M 126 80 80 42 65.5 34.5 1.90 0.9 8 9 1.07 1.26 112 
 
 
PSORATIC ARTHRITIS DATA 
 
S. No 
AGE SEX RESTSBP 
REST 
DSP 
REST 
HR SDNN Nu LF Nu HF LF/HF 30/15 
CPT 
DBP 1 
IHG 
DBP1 E/I R VR VEGF 
1 34 F 128 84 76 38 68.4 31.6 2.16 1.04 10 8 1.11 1.13 6000 
2 33 F 126 78 69 47 68.5 31.5 2.17 1.02 12 12 1.14 1.16 123 
3 22 F 126 78 69 48 73.4 26.6 2.76 1.03 11 10 1.1 1.08 2344 
4 33 F 130 80 76 36 69.6 30.4 2.29 1.12 13 8 1.12 1.14 324 
5 34 F 128 80 73 63 71.4 28.6 2.50 0.97 9 8 1.11 1.14 142 
6 23 F 120 80 72 54 67.8 32.2 2.11 0.9 10 11 1.08 1.1 146 
7 35 F 128 86 76 36 75.4 24.6 3.07 0.93 9 4 1.07 1.02 6000 
8 24 F 124 82 79 65 69.4 30.6 2.27 0.78 8 6 1.03 1.03 2345 
9 33 F 128 86 73 46 69.4 30.6 2.27 1.08 9 11 1.1 1.18 212 
10 38 F 128 84 79 42 69.4 30.6 2.27 0.87 10 14 1.04 1.11 1546 
11 25 F 128 86 81 49 62.2 37.8 1.65 1.06 11 11 1.03 1.14 6000 
12 29 F 124 86 69 52 54.5 45.5 1.20 1.06 9 9 1.05 1.13 134 
13 24 F 128 80 84 58 59.4 40.6 1.46   13 10 1.04 1.11 156 
14 38 F 126 82 69 43 74.5 25.5 2.92 0.59 11 6 1.07 1.08 6000 
15 28 F 138 80 70 67 72.4 27.6 2.62 0.92 9 11 1.18 1.16 154 
16 26 M 120 86 71 58 64.5 35.5 1.82 0.75 11 12 1.14 1.12 164 
17 38 M 132 86 76 65 67 33 2.03 0.69 13 8 1.1 1.12 164 
18 39 M 128 80 83 52 56.4 43.6 1.29 0.79 7 9 1.06 1.19 6000 
19 38 M 130 80 76 53 62.2 37.8 1.65 0.78 9 10 1.04 1.13 2348 
20 32 M 128 86 72 64 69.4 30.6 2.27 0.96 9 8 1.08 1.17 120 
21 34 M 132 80 81 39 70.4 29.6 2.38 1.09 11 11 1.09 1.12 119 
22 36 M 130 80 70 38 64.5 35.5 1.82 0.86 7 10 1.12 1.05 136 
23 35 M 130 80 75 64 65.3 34.7 1.88 0.87 11 8 1.08 1.12 214 
24 28 M 128 82 78 36 62.8 37.2 1.69 1.05 9 9 1.06 1.02 154 
25 23 M 130 82 65 34 64.3 35.7 1.80 0.76 12 10 1.01 1.01 544 
26 25 M 132 80 74 54 75.3 24.7 3.05 0.68 14 7 1.12 1.1 6000 
27 36 M 130 84 72 47 68.4 31.6 2.16 1.06 11 8 1.18 1.02 198 
28 27 M 124 80 79 54 66.3 33.7 1.97 0.85 9 10 1.14 1.03 6000 
29 26 M 126 80 69 37 72.5 27.5 2.64 1.12 7 8 1.08 1.05 124 
 38 M 136 80 74 46 66.8 33.2 2.01 0.83 12 11 1.09 1.03 190 
 
